Chemical & biochemical studies of Caspases by Henzing, Alexander John
Chemical & Biochemical 
Studies of Caspases 
Alexander John Henzing 
A thesis presented for the degree of Doctor of Philosophy 
University of Edinburgh 
( 	
Cr 
Dulce et decorum est pro patria mon 
Horace 
Dulce et Decorum Est 
Bent double, like old beggars under sacks, 
Knock-kneed, coughing like hags, we cursed through sludge, 
Till on the haunting flares we turned our backs, 
And towards our distant rest began to trudge. 
Men marched asleep. Many had lost their boots, 
But limped on, blood-shod. All went lame, all blind; 
Drunk with fatigue; deaf even to the hoots 
Of gas-shells dropping softly behind. 
Gas! Gas! Quick boys! - An ecstacy of fumbling, 
Fitting the clumsy helmets just in time, 
But someone still was yelling out and stumbling 
And floundering like a man in fire or lime. - 
Dim through the misty panes and thick green light, 
As under a green sea, I saw him drowning. 
In all my dreams, before my helpless sight, 
He plunges at me, guttering, choking, drowning. 
If in some smothering dreams, you too could pace 
Behind the wagon that we flung him in, 
And watch the white eyes writhing in his face, 
His hanging face, like a devil's sick of sin; 
If you could hear, at every jolt, the blood 
Come gargling from the froth-corrupted lungs, 
Obscene as cancer, bitter as the cud 
Of vile, incurable sores on innocent tongues, - 
My friend, you would not tell with such high zest 
To children ardent for some desperate glory, 
The old Lie: Dulce et decorum est 
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Apoptosis is a genetically programmed, morphologically distinct form of cell death that 
can be triggered by a variety of physiological and pathological stimuli. A decade of cell 
death research has identified a family of highly conserved and exquisitely specific 
proteases (caspases) that play a prominent role in the initiation and execution of this 
process. Caspases are cysteine-dependent aspartate-directed proteases responsible for the 
proteolysis of a plethora of substrates during programmed cell death. These include 
structural proteins of the cytoplasm and nucleus, components of the DNA repair 
machinery, protein kinases, signalling proteins and regulatory proteins. 
Caspases are synthesised as relatively inactive zymogens, that become activated by 
scaffold-mediated transactivation or via cleavage by upstream proteases in an 
intracellular cascade. The resulting heterotetrameric enzymes possess a unique absolute 
requirement for aspartate at the substrate cleavage site, and recognise a tetrameric 
sequence within the substrate. 
In order to assess the role of caspases in apoptotic execution, I set out to evaluate the 
synthesis of novel caspase inhibitors, which would enable the detection of active 
caspases from apoptotic whole cell extracts. First a 2,4-dinitrophenyl probe was 
designed for the affinity tagging of caspases in two-dimensional gel electrophoresis 
Second, biotinylated peptidylaldehydes were prepared which would enable the affinity 
purification of caspases from apoptotic cytosolic extracts under non-denaturing 
conditions. To enable biochemical studies of caspases I developed a method which 
permits the affinity purification of caspases. Apoptotic chicken hepatoma cell-line 
extracts were purified over an avidin column using a biotinylated probe. Finally, to 
permit the appraisal of the caspase proteomic variability between different cell types, 
and methods of apoptotic induction, and the identification of post-translational 
modifications of caspases, I developed a reproducible system for the identification of 
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Introduction 
Chapter 1 Introduction 
1.1 Overview of apoptosis 
Apoptosis research started with the proposal by Kerr et al. that there are two 
distinct types of cell death [1].  The first, necrosis (or accidental cell death), is usually the 
result of physical damage either by trauma or disease. Necrosis involves early plasma 
membrane changes leading to a loss of calcium and sodium ion balance, followed by 
acidosis, osmotic shock, clumping of chromatin and nuclear pyknosis (i.e. 
hyperchromatic nuclei). These changes are accompanied by an activation of 
mitochondrial phospholipase, loss of oxidative phosphorylation and a drop in ATP 
production with a consequential loss of synthetic and homeostatic capability. Calcium 
overload, leading to mitochondrial membrane dysfunction, finally signals a stage of 
irreversible damage. Secondary autolysis follows, involving swelling of the lysosomes, 
dilation and vesiculation of the endoplasmatic reticulum, and a leakage of enzymes and 
proteins, eventually resulting in loss of cellular compartmentalisation. This process 
involves groups of cells and results in tissue inflammation [2]. 
On the other hand, apoptosis (or programmed cell death) is a cell-autonomous 
process that requires the active participation of endogenous cellular enzymes. This 
process can be triggered by a variety of stimuli, including cytokines, hormones, viruses 
and toxic insults. The morphology of apoptosis is characterised by a distinctive pattern 
of changes: loss of cell volume, plasma membrane blebbing, chromatin condensation, 
and fragmentation into membrane enclosed vesicles (apoptotic bodies), which are 
phagocytosed by neighbouring cells [3]. This readily visible transformation is 
accompanied by a number of biochemical changes. Changes at the cell surface include 
the externalisation of phosphatidylserine [4] and other alterations that promote 
recognition by phagocytes [5]. Intracellular changes include the degradation of the 
chromosomal DNA into high-molecular-weight [6, 7] and oligonucleosomal fragments 
1 
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[8], as well as cleavage of a specific subset of cellular polypeptides [9-11]. A specialised 
family of cysteine-dependent aspartate-directed proteases [121 termed caspases 1131, 
which form the subject of this study, accomplishes these cleavages. The activation of 
caspases seems to be the biochemical event that more than any other defines a cellular 
response as apoptosis. Apoptosis is undergone by individual cells that are surrounded by 
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Fig 1.1 illustration of the morphological features of necrosis and apoptosis. 
Adapted from Boehringer Mannheim 1141. Necrotic cells have loss of membrane integrity, which begins 
with swelling of the cyloplasma and mitochondria, is followed by disintegration of organelles and ends 
with total cell lysis. Apoptotic cells exhibit membrane blebbing, aggregation of chromatin at the nuclear 
membrane, and leaky mitochondria, but manifest no loss of membrane integrity. Apoptosis starts with 
shrinking of cytoplasm and condensation of the nucleus and ends with the fragmentation of the cell into 
small membrane bound vesicles called apoplotic bodies. 
2 
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1.2 Introduction to caspases 
By 1990, apoptosis was known to be a form of cell death distinct from necrosis, 
involving a characteristic set of morphological changes and DNA fragmentation. 
Although a number of genes had been implicated in programmed cell death in 
Caenorhabditis elegans, their biochemical functions, and the degree to which these 
mechanisms were conserved in mammals, were unknown. Around this time, 
investigators in the apparently unrelated area of inflammation, were engaged in the study 
of pro-IL-IP processing, with the expectation that identification of the responsible 
protease would provide a point of departure for the development of novel therapeutic 
agents. This work led to the discovery of a novel protease, interleukin- 1 1-converting 
enzyme (ICE), now known as caspase-1. [15, 16] The connection between caspases and 
apoptosis was made when Yuan et al. reported that the product of the C. elegans death 
gene ced-3 was related to caspase- 1117].  This evidence strongly implicated the caspase 
family of proteases in a mammalian cell death pathway. 
Subsequently, 14 mammalian caspases have been reported, 12 of them in humans 
(see table 1.1). Furthermore, caspases have been cloned from the nematode 
Caenorhabditis elegans [17, 181,  the dipteran Drosophila melanogaster [19-211, and the 
lepidopteran Spodoptera frugiperda [221. The precise biological functions of several of 
these enzymes remain to be established, but it is clear that they play pivotal and distinct 
roles in both inflammation and apoptosis, raising questions about the evolutionary 
relationships between these processes. 
The structural and in vitro biochemical properties of caspases have been 
extensively studied, corroborating their role, as the highly specific proteolytic machinery 
required to mediate apoptosis. In fact, caspases are among the most selective of 
proteases, with an absolute requirement for aspartic acid at the N-terminal side of the 
cleavage site of the target protein. 
3 
Table 1.1 Selected properties of human caspases 
Caspase Old names Function Prodomain Pro Lg' Sm' Zymogenb  Substrate' LOCUSd Ref 
Caspase I ICE Inflammation CARD 45 24 14 TPLD/S YEVDJ,X 11q22.2-q22.3 [15-17] 
IL1BC 20 10 FEDD/A WEHDX 
AVQDIN 
Caspase 2 Nedd2 Initiator CARD 48 32 14 DQQD/G DVADJ,X 7q34-7q35 [23,241 
!ch-1 3 18 12 EESD/A DE1-ID,,X 
DNKD/G 
Caspase3 Apopain Effector Short 32 20 12 IETD/S DMQDX 4q33-qter+ [25] 
CPP32 17 •- 4q35 [26] 
Yama ESMD/S DEVDJX 
Caspase4 lch2 Inflammation CARD - WVRD/S LEVDX 11q22.2-q22.3 [27] 
ICEII LEED/A (W/L)EI-1DX [28] 
TX [29] 
Caspase 5 ICEIII Inflammation CARD - WVRD/S -- 1 1q22.2-q22.3 [28] 
Ty LEAD/S (W/L)EHDX 
Caspase 6 Mch2 Effector Short 34 21 13 DVVD/N VEIDI,N 4q25-q25 [30] 
18 11 TEVD/A VEHDI,X 
TETD/A 
Caspase 7 Mch3 Effector Short 34 20 12 IQADIS DEVDJ,X 10q25.1-q25.2 [31] 
CMH-1 -- DEVDX 
ICE-LAP3 DSVD/A 
Caspase 8f FLICE Initiator DED 53 43 12 VETD/S IETD,X 2q33-q34 [32] 
Mch5 55 18 11 LEMD/L LETD,X 
MACH REQD/S 
TMSDIC 
Caspase 9 Mch6 Initiator CARD 50 37 12 PEPD/A -- lp36.3-p36.1 [33] 
ICE-LAP6 35 10 DQLD/A LEHDX 
18 
Caspase 10 Mch4 Initiator DIED 55 43 12 lEAD/A IEADX 2q33-q34 [32] 
FLICE-2 17 -- [34] 
SQTD/V [35] 
Caspase 13 ERICE Inflammation ? — -- reserved [36] 
Caspase 14 '7 '7 — '7 -- 19p13.I [37] 
Adapted from Earnshaw et al. [38] 
a Multiple entries appear for partially or fully processed large and small subunits, a result of sequential cleavage at the C-terminus of the large subunit, 
followed by removal of the linker peptide from the small subunit and the prodomain from the large subunit. For additional details see [39-44]. 
b  For each caspase, the top sequence corresponds to C-terminal cleavage of the large subunit, the middle sequence corresponds to the peptide-linker 
cleavage, and the bottom sequence corresponds to the prodomain cleavage. Cleavage sites have been determined by amino acid sequencing or analysis of 
site-directed mutants [25, 28, 39, 40,43,45-48] (- no peptide linker. ? unknown). 
For each caspase, top sequence: preferred sequence reported by Talanian et al, [49], bottom reported by Thornberry et al. [50] ( - not reported). 
Reported chromosomal gene map localisation, OMIM, NCBI 
Investigators who first reported the caspase 
There appear to be different splicing forms of caspases 8, 9 and 10. 
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1.3 Primary structure 
Caspases are synthesised as zymogens with the general organisation shown in 
Figure 1.2. The length of the N-terminal prodomain varies from 23 amino acid residues 
for caspases 3,6 and 7 to over 200 in caspases 8 and 10. Embedded within some of these 
N-terminal peptides are distinct domains that are probably required for specific protein 
interactions utilised during activation of the caspases. Thus, procaspases 8 and 10 
contain tandem death effector domains (DED) required for binding to adapter proteins 
during death receptor ligation [51]. Procaspases 1, 2, 4, 5 and 9 contain a caspase 
recruitment domain (CARD) [52] that is postulated to be a protein interaction domain 
required for assembly of activation complexes. 
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Figure 1.2 Zymogen maturation 
Structures of the zymogens for caspase 8, an initiator caspase, caspase 1, a cytokine activator, and caspase 
3, an effector caspase. The amino-terminal prodomain.s (3-24 kDa) are shown in blue, large subunits (17-
21 kDa) in red, and small (10-13 kDa) subunits in yellow. The prodomain of caspases 8 and 10 contain 
two death effector domains (DEL)), that of caspases 1, 2,4, Sand 9 contain a caspase recruitment domain 
(CARD), whilst that of the effector caspases 3,6 and 7 is short. Some procaspases also contain a small 
peptide linker between the large and small subunit, which is excised during maturation. The 
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Figure 1.3 Multiple sequence alignment of human caspases 
The polypeptide sequences were aligned using the 1531 program. 
Following convention, caspasel numbering: catalytic dyad a) active site His 28' and b) active site Cys, the P 1 coordination residues c) Arg", d) Gin 283, e 
Set-339, 1) Arg' and g) SerM7, the caspase 3 subfamilies occluding h) Trp the 'oxyanion hole' i) Gly 238 and j) effector caspase loop region. For 
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Figure 1.4 Phylogenetic relationships of caspases 
Phylogenetic tree of all currently known caspases. The above tree was constructed based on alignments 
between caspase sequences generated by the ClustaiW program 1541, canceling for multiple substitutions. 
The various trees produced by the ClustaiW program were checked by re-sampling with 1(0 bootstrap 
trials and compared with neighbour-joining trees inferred using the PROTDIST and NEIGHBOR 
programs from the PHYLIP package (hup://evolution.genetics.washingtonedulphylip.html) The topology 
of the branches composing each individual subfamily was also confirmed by using the PileUp program in 
the Wisconsin Package to construct separate alignments, and subsequently using a GCG interface to the 
tree-searching options of the PAUP program (http://www.Lms.si.eduIPAUP/about..bIml)  to find the optimal 
topology by means of parsimony. Moreover, the designations of subfamilies was confirmed by analysis of 
distance matrix data, in which the mean distance between all members of the same subfamily was 
compared with the mean distance of each subfamily member from all other proteins in the tree. Finally, 
the PHYIJP and ClustaiW trees were viewed using the TreeView program 
(http/Jtaxonomy.wology.g1a.ac.uk/md/treeview.html).  
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The DED and CARD motifs resemble the death domain (DD) [55-581; all three 
domains are tightly packed bundles of 6 a-helices [59-61]. The death domain is an 
amino acid sequence motif (60-70 residues) [56] found in the cytoplasmic domain of 
certain transmembrane receptors (death receptors). The cytoplasmic domains of these 
receptors lack homology to components of known signal-transduction pathways [62, 
63](see paragraph 1.6). Significantly, the effector caspases 3, 6 and 7 have very short N-
terminal domains, with no known functional motifs. The initiator caspases 8, 10,9 and 2 
on the other hand possess large prodomains. The N-terminal peptide is followed by 
sequences encoding first a large (17-20 kDa) and then a small (9-12 kDa) subunit. In 
some procaspases, these subunits are separated by a small linker peptide, which is 
excised from the zymogen during enzyme maturation. 
In a comparison of the multiple alignments of both the large and small subunit of 
the 12 human caspases (Figure 1.3), 29 residues are identical in at least 10 family 
members. Of these, 7 are involved in substrate recognition and catalysis. The other 22 
conserved residues are scattered throughout the protein. Many of these residues are 
hydrophobic and are likely to be involved in maintenance of the overall structure of the 
native enzyme. Because relatively few of these conserved residues are exposed on the 
surface of the active enzyme, it is unlikely that they are directly involved in interactions 
with other ligands. Instead, they might be important for interactions that occur between 
procaspase chains during assembly and processing of the enzymes. Alternatively, they 
may help determine conserved structural features of the mature caspases that are 
required for their interactions with regulatory proteins. Such a role would be subject to 
strong selective pressure during evolution (for phylogenetic relationships of caspases see 
Figure 1.4 and Appendix 2). 
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1.4 Quaternary structure 
Caspases are synthesised as catalytically dormant tripartite proenzymes. The 
active caspase is composed of two large and two small subunits, which are liberated 
from the zymogen by cleavage at an aspartic acid residue. The presence of Asp at the 
maturation cleavage sites is consistent with the ability of caspases to auto-activate or to 
be activated by other caspases as part of an amplification cascade. X-ray 
crystallographic studies revealed the enzyme to be a tetramer containing two large and 
two small subunits, a homodimer of the large subunit:small subunit heterodimer 164, 
651, in a head-to-tail configuration, with two active sites at opposite ends of the 
molecule. Both large and small subunits within each heterodimer interdigitate to form a 
central core of a six-stranded n-sheet and five a-helices which are distributed on 
opposing sides of the plane that is formed by the a-sheets 164-671, a unique structure 
amongst proteases. Components of the proteolytic device, including the active site Cys 
and His residues, are harboured within the large subunit, whereas residues which form 
the S. subsite that tethers the carboxylate side chain of the essential P 1 aspartyl are 
derived from both the large and small subunits (Figure 1.5). Similarly, both the large and 
small subunits contribute residues to form the substrate binding cleft S 4-S 1 , although the 
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Figure 15 Major polar interactions within the caspase active site 
Common polar interactions in the caspase:inhibitor complex, based on caspase-1:Ac-YVAD-Cl-1O and 
caspase-3-Ac-DEVD-CHO X-ray crystal structures. The inhibitor molecule (red) is tethered by a network 
of hydrogen bonds, including those which stabilise the carboxylate side chain of the P 1 aspartate (blue), 
the catalytic dyad (black), and the main-chain interactions (green). 
Despite the presence of two active sites in the active heterotetramer, there is no 
evidence for co-operation or allosteric modulation between these sites. The overall 
configuration of the tetramer and the orientation of the individual subunits within it 
suggest a mechanism of caspase activation. In this model, two zymogens associate, 
interdigitate and process each other to form a tetramer in which each of the two 
heterodimenc domains is composed of a subunit derived from each proenzyme. This 
model is supported by the proximity of the C-terminus of a large subunit from one 
heterodimer to the N-terminus of the small subunit in the opposing heterodimer [64-671. 
The ability of certain caspase I mutants to complement each other when co-expressed 
[68] upholds this model, although the inability of caspase 9 mutants to complement one 
another [45] raises the possibility that other caspases might be matured in a different 
manner. It will probably require a proenzyme X-ray structure to validate this model. 
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Caspases have an absolute requirement for aspartate at the P 1 position 169, 70], 
are promiscuous in P2 , prefer glutamic acid at the P3 site 116, 691, but have varying 
preferences in P4. The carboxylate side chain of the P 1 aspartate fits into a highly 
restrictive pocket S I , and is tethered by hydrogen bond interactions with Arg', Gln, 
Arg', and Ser, all of which are conserved in human caspases, except that Ser is 
replaced by a Thr in caspase 8. The tight physical dimensions of S 1 account for the lack 
of tolerance for residues other than aspartate in this position. The P 2 and P3 binding sites 
(S2 and S3) are reasonably distinctive, although tolerant of broad substitutions. The 
peptide backbone of the bound substrate forms main-chain hydrogen bonds with Ser 
(conserved in most caspases) and Arg' (conserved in all caspases) as it extends along 
the binding cleft through these sites. The P4 binding site (S4), which appears to be the 
key determinant for substrate specificity, vanes markedly between different caspase 
family members. This is best exemplified in a comparison of caspase 1 and 3 where the 
S4 subsites vary radically in both geometry and chemical nature. In caspase I the S4 
subsite is a large, shallow hydrophobic depression that readily accommodates bulky 
hydrophobic side chains, such as the preferred tyrosine or tryptophan. This site 
accommodates other residues as well; hence the relative promiscuity of caspase 1. 
Caspase 3 on the other hand, has a rather narrow hydrophilic pocket that can 
accommodate small acidic side chains but excludes bulky side chains, because of an 
occluding Trp [65, 661(conserved in the caspase 3 subfamily). Another structural 
feature of the caspase 3 subfamily is a small subunit-derived surface loop that makes a 
irregular reverse turn over the active site and contributes to the formation of S 4. This 
surface loop could explain the failure of caspases to cleave certain substrates, despite the 
presence of consensus cleavage sites. Certain potential substrates might fail to dock in 
the catalytic site, due to steric hindrance by the surface loop. This loop is also a potential 
site for post-translational modifications (e.g. phosphorylation [71]),  which could 




Figure 1.6 Three-dimensional structure of caspase I (A) and caspase 3(B) 
Adapted from Eamshaw el al. 1381. Tracings of the a-carbon backbones for caspase 1 in complex with 
Ac-YVAD-CHO (A) and caspase 3 in complex with Ac-DEVD-CHO (B). Throughout the figure: (cyan) 
large subunits; (yellow) small subunits: and (white) bound tetiapeptide aldehyde inhibitors. Conserved 
residues, based on the multiple sequence alignments of Figure 13, are coloured (green) uncharged polar; 
(orange) hydrophobic; (blue) basic; and (red) acidic. 
1.5 Catalytic function and mechanism 
Analysis of the active sites of caspase I and caspase 3 revealed that the catalytic 
dyad consists of a cysteine-histidine pair, equivalent to that found in all other cysteine 
proteases. By analogy to papain 1721, it is assumed that the Cys and His catalytic 
dyad exists as a thiolate/imidazolium ion-pair, in which the sulihydryl proton has been 
abstracted by the imidazole base. Upon binding of substrate, the imidazolium functions 
to polarise the carbonyl of the scissile amide bond, enabling subsequent nucleophilic 
attack by the thiolate anion. In the tetrahedral intermediate, the negative charge on the 
oxygen is balanced by the positive imidazolium ion. The Gly in the 'oxyanion hole' 
holds a water molecule in place, which might serve as the proton donor to the amine 
nitrogen of the leaving peptide. Finally, basic hydrolysis of the acyl-enzyme by the 
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water molecule's remaining hydroxyl ion, regenerates the active site and releases the 
carboxylate peptide [73] 
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Figure 1.7 Catalytic mechanism of caspases 
Adapted from Brady el al. [73] Substrate (red), active site cysteine and histidine (black), and catalytic 
water molecule (blue) 
1.6 Caspase activation 
As mentioned in paragraph 1.2 there are 12 human caspases known to date, of 
which caspases 3, 6, 7, 8, 9, and 10 are proven to be involved in apoptosis. These 
caspases can be divided into two classes, the effector caspases, which are responsible for 
the proteolytic demise of the cell, and initiator caspases, which start the proteolytic 
cascade. Caspases 3, 6 and 7 are the major effector caspases; these proteases are capable 
of cleaving the vast majority of substrates in apoptotic cells [38]. The major initiator 
caspases are caspase 8 and 9; the zymogens of these caspases display low but detectable 
proteolytic activity [381,  and are capable of cleaving effector caspases upon activation. 
The prevalent opinion is that the activation of caspase 8 and 9 are the result of 
two distinct signalling pathways [38, 741. The activation of caspase 8 is the result of the 
death receptor pathway. This pathway starts with the ligation of one of the death 
receptors [75], as illustrated for Fas in Figure 1.8. Ligand (FasL) induced trimenzation 
of the receptor (Fas), facilitates the binding of an adapter molecule (FADD) to the 
cytoplasmic domain of the receptor through homotypic interactions between death 
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domains (DD) located near the C termini of both polypeptides [55, 56, 581. Receptor 
bound FADD can form higher-order oligomers [76, 771,  that can act as a molecular 
scaffold for the recruitment of procaspase 8 through another homotypic interaction 
between death effector domains (DED) found in the N-termini of both FADD and the 
zymogen. It is thought that the juxtaposition of multiple procaspase 8 molecules initiates 
the auto-cleavage and subsequent release of active caspase 8 [781. Caspase 8 then 
cleaves both procaspase 3 and 7, and active caspase 3 activates caspase 6. 
Mitochondrial pathway 	 Death Receptor Pathway 
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Figure 1.8 Schematic diagram of two archetypal pathways of caspase activation 
Adapted from Kaufmann and Earnshaw [79J. The death receptor pathway starts with death receptor 
ligation (illustrated for Fas) followed by receptor oligomerization, recruitment of adapter molecules 
(FADD), and activation of procaspase 8. The mitochondnal pathway involves the release of cylochrome c 
from mitochondria, binding of Apaf-1, and activation of pro-caspase 9. Once activated, caspase 8 or 9 can 
in turn activate caspases 3,6 and 7. Regulators of these two pathways are indicated in green (proapoptotic) 
and red (antiapoptotic). An arrow represents stimulation of a particular pathway, whereas a stop represents 




Caspase 9 is activated through a pathway involving the mitochondria (see Fig 
1.8). Many stimuli that trigger apoptosis cause changes in the conformation and/or 
activity of proapoptotic Bcl-2 family members (e.g. Bak and Bax)[ 80, 811 which are 
located in the outer mitochondrial membrane. As a consequence the electron transport 
protein cytochrome c is released from the intermembrane space. The apoptotic protease 
activating factor-i (Apaf- 1) binds the released cytochrome c, causing a nucleotide 
dependent conformational change [33]  that allows binding of procaspase 9 through N-
terminal caspase recruitment domains (CARD) present in both [33]. This interaction 
allows the maturation of the zymogen, resulting in the release of active caspase 9 182, 
831. The net result is the activation of caspases 3 and 7 followed by caspase 6. 
1.7 Caspase regulation 
Since caspases are the 'executioners' of apoptosis, it is hardly surprising that 
these proteases are tenaciously regulated. The generation, processing, and activity of 
caspases is regulated at various levels. 
Although apoptosis can occur in the absence of mRNA or protein synthesis [84, 
851, several observations suggest that transcriptional regulation of procaspase gene 
expression might be important under certain circumstances. Procaspase mRNAs are 
readily detected in a variety of tissue culture cells 186-901, but zymogen levels clearly 
vary among different human tissues. For example, many lymphoid and mature myeloid 
cells exhibit high levels of procaspase 3, whilst breast epithelium and normal neurones 
display low levels [91]. However, zymogen levels are not static; recent studies have 
indicated that procaspase 3 mRNA levels are elevated in mouse neurones in vitro and 
mouse brain in vivo, after apoptotic insults 192, 931. In humans zymogen gene 
expression can be affected by y-interferon. Administration of y-interferon to human 
U937 leukaemia cells can increase caspase expression and sensitivity to apoptosis [94]. 
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The mechanism of regulation of caspase gene expression by transcription factors is not 
fully understood, and requires further study. 
A group of inhibitors of death receptor mediated apoptosis, commonly known as 
v-FLIPs, (Flice-like inhibitory protein) have been identified in several y-herpes and 
moll usci pox-vi ruses [95]. These inhibitors contain two DEDs, which interact with 
FADD thereby preventing recruitment and activation of procaspases 8 and 10. This is an 
efficient strategy to neutralise the host's apoptotic response. The human analogue of v -
FLIPs, known as FLIP is an inactive homolog of caspases 8 and 10, containing, apart 
from the two DEDs, an entire caspase domain mutated in the catalytic residues as well 
as residues forming the S 1 subsite. The role of FLIP in humans is not clear, since in 
certain cases it protects the cell against receptor mediated apoptosis 196-981, whilst 
enforced overexpression in some cases can induce apoptosis 121, 96, 99, 1001. FLIPs 
may act as competitive inhibitors, preventing the binding of procaspases 8 and 10 to 
adapter molecules, thereby preventing the clustering of zymogens at the cytosolic face of 
the death receptor required for activation as discussed previously. 
The Bcl-2 family of pro- and antiapoptotic proteins appears to regulate the 
mitochondrial death pathway. The antiapoptotic Bcl-2 family members Bcl-2 and Bcl-
XL  are able to form heterodimers with the proapoptotic family members Bax, Bik, and 
Bid [101, 1021, thus possibly serving as inhibitors, by preventing the stimulation of 
cytochrome c release by these members [103, 1041. Furthermore, the antiapoptotic Bcl-
XL  appears to inhibit the recruitment of procaspase 9 to the scaffold protein Apaf-1, 
thereby preventing the activation of the zymogen [1051. 
Since apoptosis is the mechanism that is most frequently utilised as a response to 
a viral infection, it is not surprising that some viruses have developed a strategy to 
inhibit caspases. The viral inhibitors of apoptosis, which include the poxvirus protein 
CrmA, baculovirus protein p35, vFUP and lAP, exhibit the ability to prevent apoptosis 
by the regulation of caspase activation and activity [18, 106, 107]. Upon cleavage, these 
proteins undergo a conformational change and are not released from the caspase. 
Interestingly no homologs of p35 are known in mammals, and though mammals do have 
multiple homologs of the serpin CrmA, thus far none of these have been shown to be 
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targeted against caspases. The only demonstrated caspase inhibitors endogenous to 
mammals are the baculoviral LAP homologues clAP-I, cIAP-2 XIAP and NALP [108-
113]. These proteins bind to and inhibit active caspases at sub-nanomolar to sub-
micromolar concentrations [114, 115]. 
Active caspases also appear to be regulated by post-translational modification. 
Several studies have been reported in which nitric oxide (NO) donors inhibit caspases 
[116-118], possibly by nitrosylating the sulfhydryl of the active site cysteine. However, 
nitric oxide has also been reported to induce apoptosis in other models [119, 1201. 
Numerous studies have suggested that apoptosis can be regulated by protein kinases and 
phosphatases (reviewed in [71, 121-123]), although evidence that caspases might be 
targets of phosphorylation has been largely indirect. The kinases responsible for 
phosphorylation of caspases, and the physiological significance thereof require further 
evaluation (see Chapter 5). 
1.8 Substrates 
During apoptosis, only a fraction of the cellular proteome is cleaved by caspases. 
Current estimates based on comparative 2D PAGE analyses between healthy and 
apoptotic cells, predict the number of caspase substrates to be less than 200 [124]. To 
date, circa 80 caspase substrates have been identified (Appendix 3) and in most cases the 
proteolysis of these proteins during apoptosis can be rationalised. Most substrates can be 
categorised into a small number of classes of proteins: cytoskeletal, nuclear lamina, 
DNA metabolism and repair, kinases, signal transduction and gene expression, cell cycle 
regulatory and proliferation, and apoptotic regulatory proteins. 
The cumulative effects of these proteolytic cleavages during apoptosis are to a) 
disable homeostatic and repair processes, b) stop cell cycle progression, c) inactivate 
inhibitors of apoptosis, d) mediate structural disassembly and morphological changes, 
and e) label the apoptotic cell for phagocytosis. in order to negotiate these events, 
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caspases can modify the function of their substrates in one of four generic ways. For 
example, caspases can inactivate the normal biochemical function of their targets (e.g. 
PARP, ICAD), or activate them by removal of regulatory domains (e.g. PKCs). 
Alternatively, caspases can alter or invert the function of their substrates (e.g. Bcl-2 and 
Bcl-X L, which are converted from anti- to pro-apoptotic forms). Finally, caspases play 
an active role in the disassembly of the structural components of the cytoskeleton and 
nuclear scaffold (e.g. lamms, fodrin, and gelsolin). Caspase cleavage usually takes place 
at a single, discrete site within the target protein, although examples of multiplicity (e.g. 
ICAD), redundancy (e.g. Huntingtin) and nesting (e.g. PAR-P) also exist. 
Table 1.2 Substrate cleavage sites 
Stibtrn 	cftavge Cleavage site(s) Protein 
Single DQTD Gelsolin 
Nested DEVDGVD PARP 
Redundant clustered DSLD X 13 DEED X 18 DLND X32 DGTD Huntingtin 
Distal multiple DEPD X .........X DAVD ICAD 
As discussed earlier, the primary specificity for aspartate, shared only with 
grauzyme B a serine protease involved in killing cytotoxic T cells, is highly unusual 
among mammalian proteases, which implies an evolutionary conservation. Since the 
apoptotic response seems to be of fundamental importance to metazoans, a strong 
selective pressure must be in place in order to prevent other proteases from acquiring 
aspartate specificity and inadvertently triggering apoptosis. Consequently, it is likely 
that the caspase substrates required for apoptotic demise have evolved alongside the 
caspases during metazoan radiation to adapt to caspase primary specificity. The 
emergence of caspases primarily involved in cytokine activation (caspase 1, 4 & 5) 
rather than apoptotic execution is therefore remarkable. A secondary evolutionary drive 
must therefore have taken place to ensure that cytokine-activating caspases cannot 
cleave apoptotic substrates; hence the development of a tightly regulated extended 
substrate specificity (see Appendix 3). 
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1.9 Genetic analysis 
With a bewildering array of substrates being cleaved during apoptotic execution, 
it is rational to investigate which caspases are responsible for which events. Since 
caspases manifest overlapping substrate specificities, the design of specific caspase 
inhibitors has been a major challenge 11251. Genetic analysis of caspase knockout 
mutants has provided valuable information on the role of individual caspases in 
apoptosis. 
Table 13 Caspase deficient mice 
.\p 	'tc defects Other d-c'i. Rcicrcn:: 
Caspase 1 None (viable) Fas (thymocytes)? 1L-Iaj&18 processing, 1126, 127] 
endotoxin resistant 
Caspase 2 None (viable) 4 Oocytes, facial motor NO [128] 
neurons (accelerated) 
Caspase 3 t4eumnal Morphology/DNA 	frag. Brain development 1129, 130] 
Perinatally lethal' (MEF's, Hep's, Thym's) 
Caspase 6 None (viable) NO B-cell malumlion? 11311 
Caspase 7 Embryonic lethal N/D N/D 11311 
Caspase 8 Embryonic lethal Death-receptor 	pathway Heart muscle [130, 132] 
(MEFs) 
Caspase 9 Neuronal Mitochondnal 	pathway Brain development 1133, 134] 
Embryonic lethal" (thy 	cytes) 
Caspase 11 Normal Fas? (thymocytes) Caspase- 1, 	IL- 1aj&18 11351 
processing, 	endotoxin 
(LPS) resistant 
Caspase 12 Normal ER pathway [1361 
Adapted from Theng and Flavell [1311. The pennatal lethality of caspase 3 knockout mice can be 
influenced by genetic background [1371. "A very small percentage of caspase-9 knockout mice (<2%) 
develop normally. NID not determined. 
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The targeted disruptions of caspases 1, 2, 3, 6 7, 8, 9, 11 and 12 in mice have 
been reported. The general picture that emerges from these knockout studies is that no 
knockout described to date abolishes all apoptosis during embryonic development. 
Furthermore, defects in apoptosis are both cell type and stimulus dependent, suggesting 
that apoptotic pathways activate distinct caspase repertoires in different tissues and in 
response to different stimuli (see Table 1.2). 
Caspase I and 11 null mice are developmentally normal [126, 127, 1351 but are 
deficient in the production of mature interleukin-la, interleukin-1[ [126, 1271, 
interleukin-18 and y-interferon [138-140]. These knockout mice are therefore relatively 
resistant to septic shock. Dexamethasone and y-irradiation induced apoptosis appears to 
be normal in caspase 1 thymocytes. However, the response to Fas induced apoptosis 
was reported in one study to be diminished. 
Caspase 2' mice are also developmentally normal, and their cells show a normal 
apoptotic response to various stimuli [1281. Caspase 2 null B-lymphoblasts are more 
resistant to apoptosis induced by granzyme B/perform, but respond normally to anti-Fas, 
etoposide, y-irradiation, staurosporine and TNFa/cycloheximide induction. This latter 
observation is particularly interesting, since caspase 2 can be recruited to the TNFRI 
receptor through interactions with the adapter proteins RAIDD, RIP and TRADD 1141, 
1421. 
Caspase3 knockout mice can survive to birth, but exhibit perinatal mortality as a 
result of defects in brain development, a consequence of diminished apoptosis [129, 
1431. Caspase 3 null thymocytes undergo apoptosis in response to anti-Fas, 
dexamethasone, C2-ceramide, staurosporine and y-irradiation, whilst neutrophils and 
activated T cells seem to require caspase 3 for this. Cell cultures undergoing apoptosis 
do not require caspase 3 for PARP cleavage or annexin V binding, but it is essential for 
internucleosomal DNA degradation and chromatin condensation, thus suggesting a role 
for caspase 3 in nuclear apoptotic events. 
Caspase 9' mice display abnormal brain development which is similar to that 
exhibited in caspase 3' though more severe 1133, 1341. Again, the development of other 
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organs appears to be normal. Caspase 9 knockout mice display a very complex pattern of 
abnormalities in apoptotic responses, with variation in a cell type- and stimulus-specific 
manner. 
Caspase 8 null mice develop normally until embryonic day 11.5, after which they 
begin to die. Caspase 8 knockout mice display poorly developed heart musculature and 
extensive accumulation of erythrocytes in the liver, lung, mesenchymal spaces, and lens. 
Caspase 8' embryonic fibroblasts are resistant to apoptotic signalling through FAS, 
TNRI, and DR3 receptors, but remain sensitive to serum withdrawal, ultraviolet 
irradiation, ceramide and etoposide 1132]. Analysis of caspase 8 knockouts verified that 
caspase 8 is an essential and non-redundant component of certain death receptor initiated 
pathways. These studies also indicate that caspase 8 plays an essential, though poorly 
understood, role in cardiac and lymphohematopoietic development. Furthermore, these 
studies verified earlier observations [144] that certain apoptotic stimuli, like 
chemotherapeutic agents, are capable of initiating caspase activation through a pathway 
independent of FAS/FADD/caspase 8 interactions. 
1.10 Caspases as targets of therapeutic intervention 
Research into apoptosis, virtually since the discovery of this phenomenon, has 
held the promise of identifying targets whose manipulation would permit the treatment 
of several disease states. There is overwhelming evidence that apoptosis is critically 
involved in numerous pathological conditions. Diseases in which apoptosis has been 
implicated can be roughly divided into those where excess cell death occurs, like human 
immunodeficiency virus (HIV) infection [145-1471, ischemic or neurodegenerative 
disorders 1148, 1491, atherosclerosis [150, 1511, and those where insufficient cell death 
underlies the disease, such as cancer and viral infections (see Table 13). 
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Southern analysis of rodent-human hybrids and in situ hybridisation to normal 
human metaphase chromosomes allowed Cerretti et al. [15] to map the CASPI gene to 
1 1q23, a site frequently involved in rearrangement in human cancers, including a 
number of leukaemias and lymphomas. This was later confirmed by fluorescence in situ 
hybridisation (FISH) [1521. Studies in caspase I deficient mice indicated that caspase I 
knockout mice are highly resistant to the lethal effects of endotoxin [153]. These studies 
suggest the therapeutic potential of caspase 1 inhibitors in inflammatory diseases such as 
septic shock and inflammatory bowel diseases. In a mouse model for Huntington's 
disease, expressing a dominant-negative mutant of caspase 1 in the brain resulted in 
extended survival and delayed appearance of neuronal inclusions, neurotransmitter 
receptor alterations, and onset of symptoms, indicating that caspase I might be 
important in the pathogenesis of Huntington's disease. Furthermore, 
intracerebroventricular administration of a caspase inhibitor delayed disease progression 
and mortality [154], suggesting the possible therapeutic application of caspase-1 
inhibitors to human Huntington's disease. 
Table 1.4 Diseases associated with altered states of apoptosis 
V d 
cancer AIDS 
breast cancer atherosclerosis 
prostate cancer myelodysplastic syndromes 
ovarian cancer aplastic anaemia 
lymphomas myocardial infarctation 
autoimmunc disorders: stroke 
lupus erythematosu.s repeifusion injury 
glomerulo-nephritis toxin-induced liver injury 
viral infections: neurodecenerative disorders: 
herpes virus Alzheimer's disease 
pox virus Parkinson's disease 
adenovirus amyotrophic lateral sclerosis 
retinitis pigmentosa 
Adapted from Deigner and Kinscherf [1551. 
Table 1.3 shows a selection of diseases associated with altered states of apoptosis. Cancers, autoimmune 
disorders and viral infections show a decrease in apoptosis, whilst diseases such as neurodegenerative 
disorders, AIDS and stroke show an unwanted increase in apoptosis. 
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Radiation hybrid mapping localised the CASP2 gene to human chromosome 
7q35 [156]. The authors observed that each of the 4 caspase genes mapped in this study 
colocalized with an autosomal dominant malformative disease and suggested 
holoprosencephaly as a candidate genetic disease at this locus. Studies of caspase 2 
deficient mice generated contrasting results; whilst oocytes were resistant to 
chemotherapeutic drugs, and granzyme B and perforin mediated apoptosis was defective 
in B lymphoblasts, caspase 2 deficient motor and sympathetic neurons underwent 
accelerated apoptosis [128]. Thus, caspase 2 acts as both a positive and a negative cell 
death effector, depending upon cell lineage and stage of development, making 
therapeutic intervention a challenging task. 
CASP3 has been mapped to human chromosome 'k33-q35.1, and colocalized 
with an autosomal dominant malfonnative disease; William syndrome has been 
implicated as a candidate genetic disease at this locus [156]. 
CASP4 and CASP5 have been mapped to chromosome 1 1q22.2-q22.3 and 
together with CASP1 are clustered within 70 kb DNA, suggesting that the 3 genes arose 
by tandem duplication of a common ancestral gene [157]. Both caspase 4 and 5 are 
expressed in all tissues with the exception of brain, and are involved in cytokine 
activation, thus making them attractive targets of therapeutic intervention. 
In the studies mentioned above Tiso et al. [156] localised the CASP6 gene to 
human chromosome 4q25-q26, and suggested that Reiger syndrome is a candidate 
genetic disease at this locus. CASP7 was localised to 10q25.1-q25.2 and implicated with 
Crouzon craniofacial dysostosis as a genetic defect. Although these genetic diseases 
were mapped to the same region on the chromosome as the caspase genes, no evidence 
was obtained which corroborated their suspicion. 
Fluorescence in situ hybridisation mapped both the CASP8 and CASPIO genes 
to 2q33-q34. Their gene products are also closely related, indicating that the 2 genes 
have evolved by tandem duplication. Western blot analysis revealed the presence of 
activated caspase8 in the insoluble fraction of affected brain regions from Huntington's 
disease patients but not in those from controls, suggesting a role for caspase 8 in 
Huntington 's-related neumdegenerative diseases [158]. By a candidate gene mutation 
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search strategy, Wang et al. identified independent missense mutations in the CASPIO 
gene in 2 kindreds with type II autoimmune lymphoproliferative syndrome (ALPS2) 
characterised by abnormal lymphocyte and dendritic cell homeostasis and immune 
regulatory defects [159]. The mutations resulted in amino acid substitutions that 
decreased caspase activity and interfered with death receptor-induced apoptosis. These 
results provided evidence that inherited non-lethal caspase abnormalities cause 
pleiotropic apoptosis defects underlying autoimmunity in ALPS2. 
Caspase 13 is a cytokine activator closely related to the other 3 inflammation 
implicated caspases; it shares 75%, 61% and 47% identity with caspase 4, caspase 5 and 
caspase 1 respectively. Northern analysis has revealed that it is predominantly expressed 
in peripheral blood lymphocytes, spleen and placenta [361. 
Numerous studies have demonstrated that a wide variety of anticancer agents, 
including chemotherapeutic agents, hormones, and various biologicals, induce apoptosis 
in malignant cells in vitro [160, 1611. Treatment induced apoptosis does not only occur 
in in vitro studies of cell lines; in vivo studies of peripheral blood mononuclear cells 
from acute leukaemia patients undergoing induction therapy have demonstrated that 
various agents cause a marked increase in the number of apoptotic blasts [162]. 
Characteristic apoptotic changes have also been described in solid tumours after 
treatment of mice with various cytotoxic drugs [161]. The implication of anticancer 
drugs killing target cells by inducing apoptosis has had huge impact on the use of 
chemotherapeutic agents. The nature of apoptosis as a highly regulated process makes 
the interference complicated, since biochemical alterations might affect the sensitivity of 
cells to a wide range of unrelated agents [79]. 
The ability to identify targets implemented in specific diseases, without prior 
knowledge of the complexity thereof opens tremendous opportunities for the treatment 
by removal or preservation of specific cells within diseased tissue. By providing an 
understanding of how to induce apoptosis or to block its inappropriate activation in 
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specific cells apoptosis research may have an immense impact on the future treatment of 
cancer and other diseases. 
Table 1.5 Examples of anticancer treatments that induce apoptosis 
Treatment Rd. Treatment Ref. Treatment 
Antimetatxthtes Topot'ssnerasel poisons Miscellaneous agents 
Cytaratane [9] Ctun*othedn [9, 1631 P5-341 11641 
Fludarabine [1651 Topotecan [1661 Fitenythutyrate [167] 
5-Fluoro.-2'-deoxyuiidine 1I681 1oxn 	nierdse II poisons FF-I8-OCH [169. 170] 
Gemeitabine 11651 Etopoude 19, 1711 Famesyl-transfer 1nh 
Hydroxyurea 11721 Teniposide 19, 1731 1-739749 11741 
Methotrexate 191 Nficrotuhuk-iirected agents L744832 [175] 
fT'\ liagmenting agents Colcemid 191 Hormones 
Bleomycin 1176, 1771 C1i 11781 (}lucocoilicoids 18, 1791 
I)N\cross-linking agents Paclilaxel [180, 181] Fenretinide 1182, 183] 
Clorambucil [1841 Vincristined [185j Ilomw'ne antagonists 
Cisplalin [9,1861 Intercalating agents Tamoxifen [1871 
Cydophosphamide [188, 1891 Ad,iamycin [190, 1911 Finasteiide [192, 193] 
Nitrogen mustard 1194] Mitoxantrone [195] LHRJ-1 antagonists [196] 
Protein synthesis inhibitor Kinase inhibitors E3iotogicals 
L-Asparagrnase [1971 Havopitidol [198-200] Tumor necrosis factor 1201,2021 
Cydoheximide 191 Staurosporine [2031 TRAIL [204, 2051 
I'uromycin [841 ST1571 (('-PG 571488) [2061 Anti-(MM [207.208] 
Diphiena toxin [209] Hydmxyslaumspoiine [2101 Endostatin [211,2121 
Adapted from Kaufmann and Earnshaw [791 
Examples of anticancer therapeutic drugs that induce apoptosis when administered in vivo. 
The therapeutic induction of apoptosis via cell surface receptors or the 
intervention in signalling pathways has produced some encouraging leads towards 
therapeutics for diseases as diverse as osteoporosis and cancer ([2131 and references 
cited therein). 
Intervention in the inappropriate activation of the apoptotic pathway, through the 
cell surface receptors and their downstream signalling components such as the protein 
Introduction 
kinases, has provided some useful therapeutic leads for degenerative diseases ([1551  and 
references cited therein). 
Caspases, being involved in both the transduction of the apoptotic signal 
(initiator caspases) as well as the execution of cell death (effector caspases), are obvious 
targets in the therapeutic intervention of apoptosis. 
1.11 Aims of this thesis 
The main objective of this work was to synthesise novel caspase inhibitors to allow 
the affinity purification and unambiguous detection of caspases in cytosolic apoptotic 
extracts, with the ultimate goal of dissecting the constituent role of caspases during 
apoptotic execution. 
First, a novel chiral synthetic route towards peptidyl acyloxymethylketones was 
developed. The labeling of these inhibitors with a dinitrophenyl probe should allow the 
unequivocal detection of caspases by two-dimensional gel electrophoresis. 
Second, a solid phase strategy was developed for the preparation of peptidyl 
aldehydes, which could improve the affinity purification of caspases over avidin when 
equipped with a biotin affinity tag. 
Preliminary studies on the affinity purification of caspases, using a commercial Z-
EK(biotin)D-aomk affinity probe have been carried out. 
Finally, a reproducible method was developed allowing the detection of active 
caspase species on 213-PAGE. 
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Chapter 2 Synthetic approaches towards caspase inhibitors 
2.1 Introduction 
2. 1.1 Cysteine proteases 
Proteases are directly or indirectly involved in virtually every biological 
function. The omnipresence of proteases and their naturally occurring macromolecular 
substrates and inhibitors have placed them among the most studied proteins in the area 
of biochemistry. The mechanisms of action and molecular recognition properties for a 
multitude of proteases have been probed extensively, providing a large database of 
biochemical information. This wealth of information makes these proteins ideal models 
for the investigation of structure-function relationships and excellent targets for drug 
design. The proteases and their specific inhibitors from a vast array of different 
biological systems have been studied, revealing the diverse roles of proteases. 
Proteolytic activities are central to processes ranging from cell invasion associated with 
metastatic cancer to evasion of an immune response, from nutrition to intracellular 
signalling. A large number of proteases are involved in processes that are relatively non 
site-specific such as digestion, tissue degradation and protein turnover whilst others are 
implicated in the site-specific triggering of highly controlled events (e.g. caspases). 
Proteases (EC 3.4) can be categorised as endopeptidases (EC 3.4.21-99) and 
exopeptidases (EC 3.4.11-19), according to the point where they break the peptide chain. 
They can be ordered further, according to the reactive groups at the active site involved 
in catalysis: as serine (EC 3.4.21), cysteine (EC 3.4.22), and aspartic (EC 3.4.23) 
proteases and metalloproteases (EC 3.4.24) [214]. 
The proteases in which the nucleophile is the sulfhydryl group of a cysteine 
residue are known as cysteine proteases. The catalytic mechanism is similar to that of 
the serine proteases in that a nucleophile and a proton donor/general base are required, 
and the proton donor in all cysteine proteases, in which it has been identified, is a 
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histidine residue. The known cysteine proteases have been classified into 35 sequence 
families (CI-35) [215-217]. Barrett and Rawlings [2181 have proposed that these 
families have arisen from at least five separate evolutionary origins, each of which is 
represented by a set of one or more families, termed a clan. Clan CA is the largest, 
containing the papain family (Cl) and others with the Cys/His catalytic dyad. Clan CB 
contains enzymes from RNA viruses that are distantly related to chymotrypsin, and have 
a Flis/Cys dyad. The proteases of clan CC are also from RNA viruses, but have papain-
like Cys/His catalytic sites. Clan CD exclusively contains the family of caspases (04), 
with a His/Cys catalytic dyad. The clan CE contains only the adenovirus [3 protease. 
2.1.2 Cysteine protease inhibitors 
Inhibitors can be classified based on whether the inhibitor interacts with the 
active site ("active site directed") or whether it attacks another site on the enzyme 
(allosteric effectors) [2191. The inhibitors that attack the active site can be divided 
according to the type of interaction, into covalent/noncovalent and irreversible/reversible 
inhibitors. Usually reversible inhibition involves a noncovalent interaction between 
enzyme and inhibitor. A few exceptions are known, in which covalently bound 
inhibitors result in reversible inhibition because of hydrolytically labile bonding (e.g. 
peptidyl aldehydes or nitriles). Irreversible inhibitors (i.e. inactivators) always bind to 
the enzyme covalently. In practice it is often difficult to differentiate between reversible 
and irreversible inhibitors, for instance when a reversible inhibitor binds to the enzyme 
with such a high affinity that the enzyme-inhibitor complex only dissociates very slowly 
and thus appears irreversible. This type of reversible inhibitor is known as 'tight 
binding' 12201. Normally a rapid equilibrium is observed with reversible inhibitors, 
whereas reactions which result in the modification of the enzyme take place relatively 
slowly. However, there are also reversible inhibitors which only inhibit enzyme activity 
very slowly due to conformational changes following enzyme-inhibitor complex 
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formation ('slow binding'), as well as irreversible inhibitors whose reaction with the 
enzyme occurs via a non-covalent transition state and thus lead to rapid reduction of 
enzyme activity. 
Inhibitors that undergo noncovalent interactions with the enzyme can be 
subdivided into two groups: a) substrate analogues, and b) 'tight binding' inhibitors. The 
substrate analogues are similar in structure to the substrate ground state. These are the 
classical, reversible, fast-binding, competitive inhibitors [221]. This group of 'tight 
binding' inhibitors includes the transition-state analogues, which are similar in structure 
to an energy-rich intermediate, as well as to all inhibitors which can bind to several 
domains on the enzyme ('multi-domain inhibitors') [2211. 
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Fig 21 Reversible cysteine protease inhibitors 
Covalent inhibitors can be subdivided according to whether they react with the active 
site by the normal process of catalysis ("mechanism based") [2221 or by other chemical 
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pathways which do not correspond to the catalytic mechanism of the enzyme ('affinity 
labelling'). 
Mechanism based inhibitors can be further subdivided into four groups. 
a) Reaction of the inhibitor with the active site results in a product analogous to the 
transition state, which cannot react further ('transition-state analogues', e.g. peptidyl 
aldehydes). b) Inhibitors that react with the active site, producing a reactive intermediate 
which subsequently reacts with the enzyme in a reaction that is not part of the normal 
catalytic pathway. These inhibitors have been called 'enzyme activated', 'suicide', 
'Trojan Horse' or 'mechanism based' inhibitors (e.g. haloenollactones) [220, 223-2251. 
c) This group includes all inhibitors which react with the enzyme to form a covalent 
enzyme-inhibitor complex that cannot react further (e.g. peptidyl nitriles). d) Inhibitors 
that can react further by the normal catalytic pathway to corresponding products. 
However, these reactions occur so slowly that they are hardly measurable ('alternate 
substrate inhibitors', e.g. physostigmine) [2261. 
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Fig 2.2 Irreversible inhibitors 
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Affinity labelling inhibitors that react with other molecules that have functional 
groups corresponding to those of the active site, are known as 'chemically reactive 
affinity labels' (e.g. chloromethylketones). Those that do not have any activity for non-
enzymatic molecules are known as 'quiescent affinity labels' (e.g. 
acyloxymethylketones) [2211. 
Recently, extensive research has been conducted into the preparation of 
peptidomimetic inhibitors of proteases in general and caspases specifically. The main 
advantages of this type of compound over peptidyl inhibitors are increased stability in 
vivo and increased cell permeability. Examples of these inhibitors are the pynmidine-
based tetrahydropyrimidine aldehyde derivatives [2271, which inhibit papain reversibly, 
and the irreversible caspase inhibitors derived from 5-aminopyrimidin-6-one equipped 
with (1 -phenyl-3-(trifluoromethyl)-pyrazol-5-yl) (FTP), diphenylphosphinyl (DPP), or 
(2,6-dichlorobenzoyl)oxy (DCB) methylketones [2281. 
R2 	CO1 
CrOW4,  __ 	1% = PIP. DPP.Da 
Tepynmidin deivabve 	 5-Aminopyvimdin-6-one deflvatives 
Fig 2.3 Peptidomimetic inhibitors 
2.1.3 Mechanism of caspase inhibition 
In an evaluation of a large number of aspartic ketones as inhibitors of caspase- 1, 
Brady et al. [731 observed that the inhibitory behaviours of these compounds could be 
classified as reversible, inactivating, or bimodal (i.e. reversible inhibition followed by 
slow inactivation). The acyloxymethyl ketone inhibitor Z-EK(bio)D-aomk can be 
categorised as a bimodal inhibitor, with a first-order rate of conversion of the reversible 
thiohemiketal complex to the inactive thioether (see fig 2.4). The thiolate-imidazolium 
33 
Chapter 2 
ion-pair of the active site Cys and His reversibly binds to the Z-EK(bio)D-aomk 
inhibitor to form a thiohemiketal complex. Here the imidazolium functions to polarise 
the carbonyl, enabling subsequent attack by the thiolate anion. The SCC a LG dihedral 
angle thereby adopts a 180° conformation necessary for SN 2 displacement. This 
conformation places the HismNb  in a position which allows it to stabilise charge, which 
develops on the leaving group during the displacement reaction. In an irreversible SN 2 
displacement reaction the sulphur attacks the Ca-carbon,  thereby releasing 2,6-
dimethylbenzoic acid as a leaving group, resulting in the formation of a thioether bond, 
and thus the alkylated enzyme. 
H 	 H 
O 
Cys285 
Thidato-imidazoliwn ion-pair 	 Thobeniikctal 
H 	 I 
37 	 \S237I 
C285 
Alkytaled Enzyme 
FIg 2.4 Catalytic mechanism of inhibition of easpases by activated peptidyl ketones 
Adapted from Brady el al. [73]. 
2.1.4 Design of caspase inhibitors 
Structural studies of caspase-inhibitor complexes have suggested that hydrogen 
bonding with P 1 -NH, P-NH and P-CO are significant for binding, whilst that with the 
P,-NH is optional. The most potent caspase inhibitors contain a tetrapeptide sequence 
that is optimal for their target caspases. For example Ac-WEHD-CHO, containing the 
optimal recognition sequence for caspase 1, has a dissociation constant K 1 of 56 pM 
12291, similarly K 1 for caspase 3 inhibition by Ac-DEVD-CHO is 230 pM (25]. Despite 
their high potency, peptidylaldehyde inhibitors are not the caspase inhibitors of choice 
Synthetic approaches towards caspase inhibitors 
due to the reversibility of their reactions, and their slight promiscuity with other 
proteases. Acyloxymethylketone inhibitors are one of the most interesting groups of 
irreversible inhibitors for caspases. These compounds were first described as potent 
Cathepsin B inhibitors [230, 2311. Acyloxymethylketone inhibitors are highly efficient, 
having a second-order rate constant for inactivation of ca. 106  M's' [2321. Additionally, 
although acyloxymethylketones are highly reactive towards caspases, they are relatively 
inert towards other biological nucleophiles, making them excellent probes for the study 


















FIg 2.5 Model representing active site of caspase with Z-GIu-Lys(biotin)-Asp-aomk covalently 
bound to the cystelne residue 
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2.2 Synthesis of peptidyl acyloxymethylketone Inhibitors 
2.2.1 Introduction 
The sequence Z-EKD has been identified as the optimal recognition sequence for 
caspases in general and was therefore chosen as the peptidyl backbone for the novel 
caspase inhibitors. 
2.2.2 Diazomethyl ketone approach 
The synthesis of acyloxymethylketone 5 has been reported in the literature [231, 
233, 2341 and seemed therefore the most likely entry towards the synthesis of peptidyl 
acyloxymethyl ketone inhibitor 16. (Figure 2.6) 
Commercially available N-a-benzyloxycarbonyl-aspartic acid y-O-teri-butyl 
ester 1 was treated with ethyichioroformate and N-methylmorpholine at -20° to form the 
mixed anhydride 2. Subsequent treatment with diazomethane, in diethylether at 0°C 
afforded the diazoketone [23513. Although diazomethyl ketone 3 could be prepared in 
relatively good yields (>8001o), it was found that the yield plummeted when the reaction 
was scaled up. The reaction of the diazomethylketone 3 with hydrogen bromide I acetic 
acid (48% w/v) at 0°C generated bromomethylketone 12361 4. Numerous difficulties 
were encountered in this particular reaction step, with poor yields (ca. 25%) and it was 
found that the integrity of the reagents was critical. Treatment of bromomethyl ketone 4 
with 2,6-dimethylbenzoic acid and potassium fluoride in dimethylformamide afforded 
acyloxymethyl ketone [231, 2371 5 in moderate yields. Removal of the 
benzyloxycarbonyl protecting group by catalytic hydrogenation with hydrogen (1 atm) 
and Pd/C in anhydrous ethanol in the presence of 1.05 equivalents of hydrogen chloride 
produced the free amine 6 as its hydrogen chloride salt. Due to the numerous problems 
that were encountered in this synthetic strategy it was decided to discontinue this 
synthetic approach 
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Fig 2.6 Attempted synthesis of acyloxymethylketone inhibitors via diazomethylketone derivatives 
a) NMM, Ethyichiorolormate, THF, -20°C, 15 mins. b) CH 2N2, Et20, 0°C to it, 2 hrs. c) HBr/HOAc, Et 20, 0°C, 15 mins. d) KF, 2,6-dimethylbenzoic 
acid, DMF, 5 hrs. e) H 2 , Pd/C, EtOH, HCI (1.05 eq), 24 hrs. 
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2.2.3 Chiral synthesis of benzytoxycarbonyl-glutamyl-IysyI (DNP)-aspartyl-aomk 
When numerous difficulties were encountered in the synthetic strategy described 
above, a novel synthetic route was designed avoiding the risks of having a reactive 
functionality within the molecule. Another major advantage of this strategy is the ability 
to obtain the final product as a single enantiomer, a significant benefit considering the 
chiral preference of enzymes. 
D-glyceraldehyde acetomde 7 was easily prepared from D-mannitol [238]. The 
Wittig reaction of 7 with Ph 3P=CHCO2CH2CH3 in methanol on an ice bath, gave a 
separable mixture (ZIE, 8:1) of the a4-unsaturated ester 8. The reaction of 8 with neat 
benzylamine in the absence of solvent at -50°C for 2 days afforded exclusively (3R)-
benzylamino ester 9 in 75% yield [2391. Hydrogenation thereof over 10% palladium on 
charcoal in anhydrous ethanol furnished amine 10 (95%). Coupling of amine 10 with N-
a-benzyloxycarbonyl-N-E-butoxycarbonyl-lysine-succinyl ester in DCM gave dipeptide 
11 in 76 % yield. Hydrogenation thereof over 10% palladium on charcoal in anhydrous 
ethanol furnished amine 12 (951%). Coupling of dipeptide 12 with N-a-
benzyloxycarbonyl-y-O-tert-butyl-glutamyl-succinyl ester in DCM furnished tnpeptide 
13 in 78% yield. Selective hydrolysis of tripeptide analogue 13 with Montmorillonite 
K10 in a mixture of ethanol and water (5:1) afforded diol 14(73%). Esterification of 14 
with 2,6-dimethylbenzoyl chloride in pyridine/dimethylaminopyridine using DMPU as a 
co-solvent, for 2 days at room temperature produced ester 15 in a 93% yield. Several 
methods were elaborated for the oxidation step, since the ketone was sensitive to 
epiinerisation under basic conditions, and extremely electrophilic in nature. The 
procedure of Dess-Martin [2401 proved to be mildest possible condition and furnished 
virtually pure ketone 16. Deprotection thereof with 95% trifluoroacetic acid with a 
catalytic amount of water gave 17. Labelling thereof with 2,4-dinitrofluorobenzene 
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Fig 2.7 Chiral synthesis of 	 ketone 
a) Ph3P=CHCO2CH2CH3 , MeOH, 0°C. b) Benzylamine, -50 °C, 48 hrs. c) H2, Pd/C, EtOH. d) Z-Lys(Boc)-OSu, DCM, 12 hrs. e)) H 2 , Pd/C, EtCH. 1) Z-
Glu(OtBu)-OSu, DCM, 12 hrs. g) Montmorillonite, EtOH/H 20 (5:1), 75°C, 3 hrs. h) 2,6-dimethylbenzoylchionde, pyridine, DMAP, DMPU, 48hrs. I) 
Dess-Martin, 0°C to a, 4hrs. j) 95% TFA/1-120, 12 hrs. k) DNFB, NMM, DMF, 12 hrs. 
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2.3 Synthesis of peptidyl aldehyde Inhibitors 
2.3.1 Introduction 
Fehrentz et al. [2411 reported the synthesis of a novel linker, based on the 
Weinreb amide [242]. These resin-bound functionalities enable the solid phase synthesis 
of aldehydic peptides by reduction with lithium aluminium hydride. The major 
advantage of this approach is the ability to synthesise peptidyl aldehydes without 
racemisation. 
2.3.2 Synthesis of benzyloxybonyl-glutamyt-Iysyl-aspartal 
Commercially available Weinreb amide resin 19 was treated with 5% piperidine 
in dichioromethane / dimethylformamide (1:1) followed by 20% piperidine in 
dimethylformaniide to yield O-methylamine 20. The aspartic residue was coupled with 
HATU/ diisopropylethylamine in dichioromethane to yield the aspartyl Weinreb amide 
21 with a substitution of 0.45 mmole/ g resin. Removal of the fluorenylmethoxycarbonyl 
protecting group by treatment with piperidine in dimethylformamide gave free amine 22. 
Coupling of the lysine residue with PyBOP/DIPEA in dimethyfformamide gave 
dipeptidyl analogue 23. Deprotection thereof with piperidine in dimethylformamide 
produced free amine 24. The benzyloxycarbonyl-glutamyl residue was attached using 
PyBOP/DIPEA in dimethylformamide yielding tripeptidyl Weinreb amide 25. 
Subsequent treatment with lithiumaluminium hydride in anhydrous tetrahydrofuran 
afforded benzyloxycarbonyI-glutamyl(OBu)-lysyl(Boc)-aspart(O tBu)al 26. Deprotection 



















Fig 2.8 Solid phase synthesis of benzyloxycarbonyl-glutamyl-lysyl-aspartal 
a) piperidine, DCM/DMF, 30 mins. b) Fmoc-Asp(OBu)-OH, HATU, DIPEA, DCM, 30 mins. c) piperidine, DMF, 30 mins. d) Fmoc-Lys(Boc)-OH, 
PyBOP, DIPEA, DMF 30 mins. e) piperidine, DMF, 30 mins. I) Z-Glu(OtBu)-OH, PyBOP, DIPEA, DMF, 30 mins. g) LiAII-L3, THF, 30 mins. h) 25% 
TFA, DCM, 30 mins. 
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23.3 Synthesis of valyl-glutamyl-isoleucinyl-aspartal 
Weinreb amide resin 19 was treated with 5101b piperidine in dichioromethane / 
dimethylformamide (1:1) followed by 20 01b piperidine in dimethylformamide to yield 0-
methylamine 20. The aspartic residue was coupled with HATU/ diisopropylethylamine 
in dichloromethane to yield the aspartyl Weinreb amide 21. Removal of the 
fluorenylmethoxycarbonyl protecting group by treatment with piperidine in 
dimethylformamide gave free amine 22. Coupling of the isoleucine residue with 
PyBOP/DIPEA in dimethylformamide gave dipeptidyl analogue 28. Deprotection 
thereof with piperidine in dimethylformamide produced free amine 29. The glutamyl 
residue was attached using PyBOP/DIPEA in dimethylformamide yielding tripeptidyl 
Weinreb amide 30. Deprotection with piperidine/dimethylformamide gave free amine 
31. Coupling of the valine residue with PyBOP/DIPEA in dimethylformamide gave 
tetrapeptide analogue 32. Removal of the fluorenylmethoxycarbonyl gave tetrapeptidyl 
Weinreb amide 33. Subsequent treatment with lithiumaluminium hydride in anhydrous 
tetrahydrofuran afforded valyl-glutamyl(O tBu)-isoleucinyl-aspart(O'Bu)al 34. 
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Fig 2.9 Solid phase synthesis of valyl-glutamyl-Isoleuclnyl-aspartal 
a) piperidine, DCM/DMF, 30 mins. b) Fmoc-Asp(O tBu)-OH, HATU, DIPEA, DCM, 30 mins. c) piperidine, DMF, 30 mins. d) Fmoc-Ile-OH, PyBOP, 
DIPEA, DMF 30 mins. e) piperidine, DMF, 30 mins. f) Fmoc-GIu(O tBu)-OH, PyBOP, DIPEA, DMF, 30 mins. g) piperidine, DMF, 30 mins. h) Fmoc-
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2.4 Materials and Methods 
2.4.1 General Procedure 
All starting materials were purchased from commercial sources (Acros, Aldrich, 
Bachem, Nova Biochem, PerSeptive Biosystems, Pierce and Sigma), and used without 
further purification unless otherwise stated. 
Thin layer chromatography was carried out on aluminium sheets precoated with Merck 
60 F254  silica. Compounds were visualised by UV absorption at 254 nm, and treatment 
with phosphomolybdic acid, ninhydrin, potassium permanganate or vanillin dip. Column 
chromatography was performed on Merck silica 60 (230400 mesh). High Performance 
Liquid Chromatography was carried out on a Gilson 712 HPLC system, using 
acetomtrile and water containing 0.1% trifluoroacetic acid. 
Melting points were determined on a Griffin melting point apparatus and are 
uncorrected. 
Infrared (IR) spectra were recorded on a Jasco FT'/IR 410 spectrometer. Samples were 
prepared as liquid films, nujol mulls or potassium bromide pellets. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on Oxford Gemini 200 and 
Bruker AC 250, 360 or 600 spectrometers. Compounds were dissolved in either CDC1 3 , 
CD2CI21  C43013 or C2D6SO purchased from Apollo Scientific. The chemical shifts (a) 
are given in ppm relative to TMS, and the coupling constants (J) are in Hz. 
Fast Atom Bombardment mass spectra were recorded on a Kratos MS 50 TC instrument 
using glycerol, thioglycerol or NOBA as the matrix. Electronspray lonisation and 
Chemical lomsation mass spectra were recorded on a MicroMass platform II 
spectrometer with acetonitrile as the solvent, unless otherwise stated. 
Solvents used were dried and redistilled under a argon flow unless otherwise stated and 
either stored over a suitable drying agent or freshly distilled before use 12431. 
Dichioromethane was distilled from calcium hydride and either stored over 4A 
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molecular sieves or used directly. Diethylether was distilled directly before use from 
sodium and benzophenone. Diisopropylethylamine was distilled over potassium 
hydroxide and stored under nitrogen. Dimethylformamide was distilled under reduced 
pressure, and stored over 4A molecular sieves. Absolute ethanol was refluxed with 
freshly ignited calcium oxide for 6 hours, left to stand overnight, distilled, and stored 
over 4A molecular sieves. Methanol was refluxed over magnesium and iodide, distilled 
and stored over 4A molecular sieves. 
2.4.2 Diazornethyl ketone approach 




OY:I~ Ce Hf 0 
CHN07 MW=  395.41 
N-a-Benzyloxycarbonyl-B-O-tert-butyl aspartic acid 1 (1.00 g, 2.93 mmole) and N-
methylmorpholine (0.45 ml, 0.42 g, 4.10 mmole) were dissolved in anhydrous 
tetrahydrofuran (10.0 ml) and cooled to -20 °C under an argon flow. Ethyichioroformate 
(037 ml, 0.42 g, 3.81 mmole) was added dropwise and stirring was continued for 15 
minutes. The reaction mixture was filtered, the residue rinsed with anhydrous 
tetrahydrofuran, and the combined filtrates and washings evaporated in vacuo to afford 
N-a-benzyloxycarbonyl-13-O-tert-butyl aspartyl ethyl anhydride 2, which was used 
directly in the next reaction step. 
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N-a-Benzyloxycarbonyl-B-O-tert-butyl aspartyl diazomethylketone 3 
COtBu 
%OXNXr NCITOO""   
C17HN307 Mw = 34939 
The mixed anhydride 2 (1.15 g, 2.93 mmole) was added to a solution of ethanol free 
diazomethane (6.0 mmole) in diethylether (50 ml) at 0 °C. After stirring for 2 hours, the 
reaction mixture was allowed to warm to room temperature, and stirring continued for 
another hour. After removal of the solvents under reduced pressure, followed by 
crystallisation from methanol/water, N-a-benzyloxycarbonyl-B-O-tert-butyl aspartyl 
diazomethylketone 3(900 mg, 841%) was obtained as a colourless oil. 
I 	 t 	 t 
H-NMR (CDC1 3 ): 1.41 (s, 9H, Bu), 2.63-3.00 (m, 1H, CH), 4.31 (dd, 2H, CH2CO2 Bu), 
4.74 (m, 1H, COCHN 2), 5.12 (s, 2H, CH2Ph), 5.80 (d, 1H, NH), 734 (m, 5H, ArH) 
13C-NMR (CDCI3): 12.5 (CH), 26.5 ( tBu), 36.1 (CI-L2CO2tBu), 49.2 (CHNH), 64.6 
(C(CH3)3), 65.9 (COCH20), 81.1 (CH2Ph), 126.8, 127.2 & 134.7 (3 x ArC), 154.5 
(CONH), 164.6 (CO2tBu), 174.7 (COAr) and 199.1 (CO) 
N-ct-Benzyloxycarbonyl-B-O-tert-butyl aspartyl bromomethylketone 4 
COBu 
CrO--I-N -- 	Br 
C 17HBrNO5 Mw = 400.27 
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N-a-Benzyloxycarbonyl-B-O-tert-butyl aspartyl diazomethylketone 3 (1.0 g, 2.88 
mmole) was dissolved in anhydrous diethyl ether, cooled to 0 °C, and hydrogen bromide 
in glacial acetic acid (3.0 ml, 48% w/v) was added dropwise whilst stirring vigorously. 
When gas evolution ceased (15 mm), the ethereal layer was repeatedly extracted with 
water (10 x 25 ml) until neutral, dried over magnesium sulfate, filtered and concentrated 
in vacuo to produce N-a-benzyloxycarbonyl-B-O-tert-butyl aspartyl bromomethylketone 
4(253 mg, 22%) which was used without further purification. 
N-a-Benzyloxycarbonyl-B-O-tert-butyl aspartyl 2,6-dimethylbenzoyloxymethylketone S 
CO1Bu 0 
CH31 NO7 Mw = 469.54 
N-a-Benzyloxycarbonyl-B--O-tert-butyl aspartyl bromomethylketone 4 (200 mg, 0.50 
mmole) was dissolved in anhydrous dimethylformamide (5.0 ml) and anhydrous 
potassium fluoride (73 mg, 1.25 mmole) and anhydrous 2,6-dimethylbenzoic acid (90 
mg, 0.60 mmole) were added. After the reaction had gone to completion, 5 hours, the 
product was extracted into diethylether (10 ml), washed with water (3 x 10 ml), dried 
over magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
reaction product was crystallised from ethyl acetate/hexane to yield N-a-
benzyloxycarbonyl-13-0-tert-butyl aspartyl 2,6-dimethylbenzoyloxymethylketone 5 (110 
mg, 47%). 
' H-NMR (CDCI 3): 1.42 (s, 9H, tBu), 238 (s, 6H, 2 x C!!3), 2.80 (m, IH, CH), 3.50 (q, 
2H, CH2CO2tBu), 3.74 (s, 2H, COCH20), 5.17 (s, 2H, CH2Ph), 5.98 (d, 1H, NH) and 
730 (m, 8H, ArH) 
47 
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13 	 t 	 t 
C-NMR (0303): 19.7 (Bu), 27.6 (2 x CH3), 363 (CH2CO2 Bu), 54.4 (CHNH), 66.5 
(C(CH3)3)
1 
 67.2 (COCH20)1  82.0 (CH2Ph), 127.4-1353 (8 x ArC), 156.1 (CONH), 
168.8 (CO2tBu), 174.7 (COAr) and 200.7 (CO) 
B-O-tert-Butyl aspartyl 2,6-dimethylbenzoyloxymethylketone 6 
HNX( 0) 
CHNO5 Mw =335.40 
N-a-Benzyloxycarbonyl-B-O-tert-butyl aspartyl 2,6-dimethylbenzoyloxymethylketone S 
(110 mg, 0.23 mmole) was dissolved in anhydrous ethanol in the presence of 1.05 
equivalents of hydrogen chloride. Palladium on carbon (10 01b wlw) was added and the 
reaction mixture was flushed with hydrogen. The reaction mixture was stirred overnight 
under a hydrogen atmosphere (1 bar). The reaction mixture was filtered through Celite 
and concentrated in vacuo. Crystallisation of the crude product from ethylacetate/hexane 
gave B-O-tert-butyl aspartyl 2,6-dimethylbenzoyloxymethylketone 6(21 mg, 27%). 
I 	 t 
H-NMR (CDCI 3): 1.42 (s, 9H, Bu), 238 (s, 6H, 2 x CH3), 2.80 (m, IH, Cl!), 3.50 (q, 
2H, CH2CO2tBu), 3.74 (s, 2H, COCH20) and 5.98 (d, 1H, NJ!) 
13 	 t 	 t 
C-NMR (CDC1 3 ): 19.7 (Bu), 27.6 (2 x CH 3), 363 (C1-12CO2 Bu), 54.4 (CHNH2), 66.5 
(C(CH3)3)
1 
 67.2 (COCH20)1  127.4-1353 (4 x ArC), 156.1 (CONH), 168.8 (CO 2tBu), 
and 200.7 (CO) 
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2.4.3 Chiral synthesis of benzyloxycarbonyl-glutamyl-lysyl(DNP)-aspartyl-aomk 
(R)-trans-4,5-O-lsopropylidene-4,5-dihydroxy-2-pentenecarboxylic acid ethyl ester 8 
H'L" Q 
C 101' 1604 Mw = 200.23 
D-Glyceraldehyde acetonide 7 (1.00 g, 7.70 mmole) was treated with 
triphenyiphosphine acetic acid ethyl ester (2.57 g, 8.10 mmole) in methanol (10 ml) at 0 
°C. After completion of the reaction, 2 hours, the product was extracted into ethyl 
acetate (50 ml) washed with water, dried over magnesium sulphate, filtered and 
concentrated tinder reduced pressure to yield a mixture of the a,B-unsaturated ester (Z:E, 
8:1). Flash column chromatography with ethyl acetate/hexane gave (R)-trans4,5-0-
isopropylidene-4,5-dihydroxy-2-pentenecarboxylic acid ethyl ester 8 (1.00 g, 70%) as a 
colourless oil. 
RI (5% MeOHIDCM) = 0.85 
MS (thioglycerol): MH201.11241 expected: 201.11280 
' H-NMR (CDCI 3): 1.26 (t, 3H, CH20H), 139 (d, 6H, 2 x CH3), 3.64 (t, IH, CH20), 
4.16 (t, 1H, CH20), 4.17 (m, 2H, OCH2CH1), 4.60 (q, IH, =CHCH), 6.06 (dd, IH, 
=CHCH) and 6.85 (dd, 1H, C=CHCO2Et) 
13C-NMR (CDC1 3): 12.7 (OCH2CI-1 3), 243 (Cl-I3), 25.0 (CH3), 59.2 (C(CH2 )2), 67.4 
(OCH2CH3 )
1 








C17HNO4 Mw = 30738 
(R)-transs-O-lsopropylidene-4,5-dihydroxy-2-pentenecarboxylic acid ethyl ester 8 
(400.5 mg, 2.0 mmole) was stirred with benzylamine (437 uI, 429 mg, 4.0 mmole) at - 
50°C for 48h in the absence of solvent. After completion the reaction mixture was taken 
into ethylacetate (25 ml), washed with water, dried over magnesium sulfate, filtered and 
concentrated in vacuo. Flash column chromatography with ethylacetatelhexane (20/1) 
afforded (R)-zrans-4,5-O-isopropylidene-4,5-dihydroxy-3-benzylamino-pentane-
carboxylic acid ethyl ester 9(460 mg, 75%) as a colourless oil 
RI (5% MeOHIDCM) = 0.70 
MS (thioglycerol): MH 308.8593 expected: 308.18630 
'H-NMR (CDCI 3): 1.24 (t, 3H, CH2CH3), 136 (d, 6H, 2 x CH), 1.82 (br. s, 1H, NI!), 
2.46 (m, 2H, CH2CO2Et, 3.13 (q, 1H NC!!), 3.81 (t, 2H, OCH2CH3), 4.00 (m, 2H, 
CH2Ar), 4.12 (m, 3H, CHO ± CH20) and 730 (m, 5H, Ar) 
13C-NMR (CDC1 3): 13.4 (OCH2 CI-1 3), 24.4 (CH), 25.7 (Cl-I 3 ), 35.4 (CH2CO2Et), 50.7 
(CJ-I2Ar), 55.1 NCH), 59.8 (OCH2CH1 ), 65.5 (C(CH2)2), 75.8 (CH20), 108.5 (CHO), 
1263, 127.5, 127.7 and 139.7 (Ar) and 171.4 (CO2Et) 
WE 
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(R)-trans-4,5-O-Isopropylidene-4,5-dihydroxy-3-amino-pentanecarboxylic acid ethyl 
ester 10 
H2N)(::- 0 o 
o-f 
CH19NO4 Mw = 217.26 
Reduction 	of 	(R)-irans-4,5-O-lsopropylidene-4,.5-dihydroxy-3-benzylamino- 
pentanecarboxylic acid ethyl ester 9 (460 mg, 1.50 mmole) with hydrogen and 10 01b 
palladium/carbon in anhydrous ethanol (25 ml) under atmospheric pressure for 12 h 
gave the crude oxalate. Column chromatography with 1-10 91b acetone/dichloromethane 
afforded (R)-trans-4,5-O-isopropylidene-4,5-dihydroxy-3-amino-pentane-carboxylic 
acid ethyl ester 10 (279 mg, 86%) as a colourless oil. 
RI (5% MeOHIDCM) = 0.25 
MS (NOBA): MH218. 13930 expected: 218.13935 
' H-NMR (CDCI 3 ): 1.19 (t, 3H, OCH2CH3), 1.27 + 1.35 (2 x s, 6H, 2 x Cl!,), 2.02 (s, 
2H, NH2, 233 (m, 2H, CH2CO2E0, 3.13 (m, 1H, NC!!), 3.68 (m, 1H, CHO), 3.99 (m, 
2H, OCH2CH3) and 4.08 (m, 2H, CH20) 
13Crsiiv1R (CDCI 3): 12.9 (OCH2CH3), 243 + 25.5 (2 x CH 3), 37.6 (CH2CO2Et), 49.2 
(OCH2CH3)
1 
 593 (C(CH 3)3), 65.0 (CHNH2), 75.6 (CH20)1  108.0 (CHO), 170.6 (CO2Et) 




isopropylidene-4,5--dihydroxy-3-amino-pentanecarboxylic acid ethyl ester 11 




C 29H45N309 Mw = 579.68 
(R)-trans-4,5-O-lsopropylidene-4,5-dihydroxy-3-anuno-pentane-carboxylic acid ethyl 
ester 10 (279 mg, 1.28 mmole) was added to a solution of N-ct-benzyloxycarbonyl-N-E-
tert-butoxycarbonyl-lysine N-hydroxysuccinimide ester (673 mg, 1.41 mmol) in dry 
dichloromethane (10 ml) and stirred overnight at room temperature. Upon completion 
the reaction mixture was taken into dichioromethane, washed with water, dried over 
magnesium sulphate, filtered and concentrated in vacuo. Column chromatography with 
0-10010 acetone in dichioromethane afforded 3-N-(N-a-benzyloxycarbonyl-N-E-tert-
butoxycarbonyl-lysyl)-(R)-trans-4,5-O-isopropylidene-4,5-dihydroxy-3-amino-pentane-
carboxylic acid ethyl ester 11 (632 mg, 85%) as a colourless oil. 
RI (5% MeOHIDCM) = 0.45 
MS (NOBA): MH 58032342 expected: 58032352 
13 
C-NMR (CDC1 3): 133 (OCH2CH3), 21.7 (Cl-I2), 24.0 (CH2), 25.4 (C(CH2)2), 27.7 
( tBu), 28.9 (CH2), 31.0 (CH2) 36.1 (Cl-I 2CO2Et), 35.9 (CH), 45.9 (NHCHCOCH20)1  
54.5 (CHN), 60.1 (C(CH2 )2) 1  65.2 (C(CH2)3), 66.2 (C(CH2)2), 75.5 (COCH20), 78.2 
(CI-l2Ph), 108.6 (COCH 20), 127.4, 127.8, 135.7 (ArC), 155.6 (CONH), 1703 (G02)1  
and 171.4 (G02) 
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N-E-terr-Butoxycarbonyl-lysyl)-(R)-irans-4,5-O-isopropylidene-4,5-dihydroxy-3-amino-






C21H39N307 MW=  445.55 
Hydrogenation of (N-a-benzyloxycarbonyl-N-E-rer:-butoxycarbonyl-lysyl)-(R)-trans-
4,5-O-isopropylidene-4,5-dihydroxy-3-amino-pentanecarboxylic acid ethyl ester 11 (632 
mg, 1.09 mmole) with hydrogen and 10 010 palladium/carbon in anhydrous ethanol (25 
ml) under atmospheric pressure for 3-4 h gave the crude amine upon filtration and 
concentration in vacuo. Column chromatography with 1-1001b acetone/dichloromethane 
gave N-E-rerr-butoxycarbonyl-lysyl)-(R)-rrans-4,5-O-isopropylidene-4,5-dihydroxy-3-
amino-pentanecarboxylic acid ethyl ester 12 (446 mg, 92%) as a colourless oil. 
RI (10010 MeOHIDCM) = 0.55 
MS (NOBA): MW446.28661 expected: 446.28674 
13C-NMR (CDC1): 133 (OCH2CH3), 21.7 (CH2) ' 24.0 (CH2), 25.4 (C(CH2 )2), 27.6 
(tBu), 28.8 (CH2), 33.0 (GH2)' 36.1 (CH2CO2Et), 39.2 (CH2 ) ' 45.9 (NHCHCOCH20)1  




 75.4 (COCH20), 77.8 (CH2Ph), 108.5 
(COCH20), 155.4 (CONH), 170.2 (CO2), and 1733 (G02) 
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Y V'-N 	0 Cr H 0 r. H 
41-1 
N HBoc 
C38F1N40I 2 Mw = 764.90 
(NEtertButoxycarbonyl-lysyl)-(R)-trans-4,5-O-isopropy1idene-4,5-dihydrOXY-3-
amino-pentanecarboxylic acid ethyl ester 12 (446 mg, 1.00 mmole) was added to a 
solution of N-a-benzyioxycarbonyl-y-O-tert-butyl-glutamyl N-hydroxysuccinimide ester 
(478 g, 1.1 mmol) in dry dichloromethane (10 in]) and stirred overnight at room 
temperature. Upon completion the reaction mixture was taken into dichioromethane, 
washed with water, dried over magnesium sulphate, filtered and concentrated in vacuo. 
Column chromatography with 0-20 010 acetone in dichioromethane afforded (N-a-
benzyloxycarbonyl-y-O-tert-butyl-glutamyl-N-e-tert-butoxycarbonyl-lysyl)-(R)-traflS-
4,5-O-isopropylidene-4,5-dihydroxy-3-amino-pentanecarboxYliC acid ethyl ester 13 (620 
mg, 81%) as a colourless solid (m.p. = 62-63 °C). 
RI (1001b MeOH/DCM) = 0.60 
MS (NOBA): MW 765.42859 expected: 765.42872 
13 
C-NMR (CDCI3): 13.9 (OCH2CH3), 223 (CR 2), 24,2 (CR2), 25.8 (C(Cl-12)2), 273 
( t Bu), 27.9 ( tBu), 283 (CH2), 29.1 (CH2) 1  292(CR2), 36.5 (CH2CO2Et), 39.9 (CR2)1  
(NHCHCOCH20), 48.2 (OCH2CH3 ) 1  53.1 (CHN), 54.6 (Cl-IN), 60.6 (C(CH2)2), 65.9 
(C(CH2)2) 1  66.9 (C(CH2)2), 75.7 (COCH20)1  80.9 (CH2Ph), 107.9 (COCH20)1  120.5-
136.0 (ArC), 142.7 (CONH), 155.9 (CONH), 156.0 (CONH), 170.7 (CO2)1170'9  (CO2)1 
171.2 (G02) and 172.6 (G02) 
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(3-N-(N-a-Benzyloxycarbonyl-y-O-tert-butyl-glutamyl)(N-E-tert-butoxycarbonyl-lysyl)-















C35HN4012 Mw = 724.84 
(3-N-(N-a-Benzyloxycarbonyl-y-O-tert-butyl-glutamylXN-E-tert-butoxycarbonyl-lysyl)-
(R)-trans-4,5-O-isopropylidene-4,5-dihydroxy-3-amino-pentanecarboxylic acid ethyl 
ester 11 (100 mg, 0.13 mmole) was stirred with Montmorillomte K10 in ethanol/water 
5:1) at 75 °C for 3 hours. After completion the suspension was filtered through Celite 
and taken into ethylacetate, washed with water, dried over magnesium sulfate, filtered 
and concentrated in vacuo. Column chromatography with 0-50 010 
acetone/dichloromethane 	yielded 	(3-N-(N-a-benzyloxycarbonyl-y-O-lert-butyl- 
glutamyl)(N-E-tert-butoxycarbonyl-Iysyl)-(R)-trans-4,5-dihydroxy-3-amino-
pentanecarboxylic acid ethyl ester 14 (66 mg, 70%) as a colourless oil. 
RI (10% MeOHJDCM) = 035 
MS (NOBA): MW 72539867 expected: 72539742 
'3 	 t 	 t C-NMR (CDCI 3): 13.4 (OCH2CH3), 21.9 (GH2), 273 (Bu), 27.7 (Bu), 28.6 (GH 2), 
30.9 (CH2), 33• 35.9 (GH2CO2Et), 39.7 (CH), 47.1 (NHCHCOCH 20)1  52.8 
(GHN), 53.9 (CHN), 60.6 (CH 20H), 62.5 (CH20H), 66.4 (C(CH3)3) 1  72.2 (OCH2CH3), 
80.4 (CH2Ph), 127.4, 127.8, 135.6 (ArG), 155.9 (CONH), 170.9 (G0 2), 171.8 (G02), 








0 ccr H  0 	 OH 
NHBOC 
CHN40 13  MW= 857.00 
(N-a-Benzyloxycarbonyl-y-O-tert-butyl-glutamyl )(N-i-rert-butoxycarbonyl-lysy1)-(R)-
trans-4,5--dihydroxy-3-amino-pentanecarboxylic acid ethyl ester 14 (66 mg, 91 tmole) 
was added to a stirring solution of DMAP (22 mg, 0.18 mmole), DMPU (23 mg, 21 IAI, 
0.18 mmole) and 2,6-dimethylbenzoyl chloride (17 mg, 0.10 mmole) in dry pyridine. 
Upon completion, 3 days, the reaction mixture was taken into dichioromethane, washed 
with water, dried over magnesium sulphate, and concentrated in vacuo. Column 
chromatography with 0-20% acetone/dichloromethane gave (N-a-benzyloxycarbonyl-y-
O-tert-butyl-glutamyl)(N-E-tert-butoxycarbonyl-lysyl)-(R)-trans-3-amino-4-hydroxy-5-
(2,6-dimethylbenzoyl)-pentanecarboxylic acid ethyl ester 15 (56 mg, 72%) as a 
colourless oil. 
RI (10010 MeOHIDCM) = 0.65 
MS (thioglycerol): 857.45472 expected: 857.45493 
' C-NMR (CDC1 3): 13.9 (OCH2CH3)
1 
 19.2(2 x CU3), 22.0 (Cl-I2), 273 ('Bu), 27.7 (tBu), 
28.7 (CU2), 30.5 (CH2), 31.1 (CH2), 34.1 (CH2CO2Et), 39.9 (Cl-I2), 51.6 
(NHCHCOCH20), 52.6 (CHN), 543 (GUN), 60.6 (CH20), 663(C(CH 3)3 ), 66.5 
(C(CH3)3 )
1 
 75.8 (COCH20), 80.6 (CH2Ph), 1  127.0-135.6 (ArC), 155.9 (CONH), 156.0 
(CONH), 168.4 (CO2 ) 1 1713 (GO2), 171.4 (G02). and 172.4 (G02) 
Synthetic approaches towards caspase inhibitors 
(N-a-Benzyloxycarbonyl-y-O-tert-butyl-glutamyl )(N-i-ter:-butoxycarbonyl-Iysy1)-(R)-
trans-3-aniino-4-oxo-5-(2,6-dimethylbenzoyl)-pentanecarboxylic acid ethyl ester 16 
CQ2tBu 
HWX 
.2 H 0 
NHBoc 
C44H62N40J3 MW=  854.98 
(N-a-Benzyloxycarbonyl-y-O-:ert-butyl-glutamyl)(N-E-tert-butoxycarbonyl-lysyl)-(R)-
trans-3-amino-4-hydroxy-5.-(2,6-dimethylbenzoyl)-pentanecarboxylic acid ethyl ester 15 
(56 mg, 65 itmole) was placed in a round bottomed flask and dry dichioromethane was 
added. Dess-Martin periodinane (0.92 ml, 138 mg, 0325 mmol) in dichioromethane was 
added drop-wise and the reaction was allowed to stir overnight. Upon completion the 
reaction mixture was taken into dichioromethane, washed, dried over magnesium 
sulphate and concentrated in vacuo. Flash column chromatography with 0-10 010 acetone/ 
dichloromethane gave (N-a-benzyloxycarbonyl-y-O-tert-butyl-glutamyl N-E-tert-
butoxycarbonyl-lysyl)-(R)-Irans-3-amino-4-oxo-5-(2,6-dimethylbenzoyl)-
pentanecarboxylic acid ethyl ester 16 (44 mg, 8001o) as a colourless oil. 
RI (10% MeOHIDCM) = 0.65 
MS (thioglycerol): MW855.43916 expected: 855.43928 
13 	 t 	 t 
C-NMR (CDCI 3): 13.9 (OCH2CH3), 19.2 (2 x CH 3 ), 22.0 (GH2), 273 (Bu), 27.7 (Bu), 
28.7 (CH2), 30.5 (012), 31.1 (CH2), 34.1 (GH2CO2E0, 39.9 (CH), 51.6 
(NHCHCOCH 20), 52.6 (CHN), 543 (CHN), 60.6 (CH20), 663(C(CH3)3 )
1 
 66.5 
(C(CH3 )3), 75.8 (COCH20)1  80.6 (CH2Ph), 1  127.0-135.6 (ArG), 155.9 (CONH), 156.0 




dimethylbenzoyl)-pentanecarboxylic acid 17 
CO2H 
0  H 
0 4~ 
0 




C33FI4 N4011 Mw = 670.71 
(N-a-Benzyloxycarbonyl-y-O-zert-butyl-glutamyl)(N-E-tert-butoxycarbonyl-lysyl)-(R)-
trans-3-amino--4-oxo-5-(2,6-dimethylbenzoyl)-pentanecarboxylic acid ethyl ester 16(5.0 
mg, 5.8 &mole) was dissolved in nitroethane (2 ml) and 2M HO was added drop-wise. 
Upon completion, 12 hrs, the reaction mixture was extracted with dichioromethane, 
dried over magnesium sulphate, and concentrated in vacuo to yield crude (N-a-
benzyloxycarbonyl-glutamyl-lysyl)-(R)-irans-3-amino-4-oxo-S-(2,6-dimethylbenzoyl)-
pentanecarboxylic acid 17 (3.1 mg, 80%). 
RI (10010 MeOHIDCM) = 0.05 
MS (NOBA): MHNa6943 1891 expected: 6943891 
13 
C-NMR (CDCI 3 ): 173 (2 x C1-13), 21.2 (CH2), 25.4(2 x G112), 26.9 (CH2), 31.1 (Cl-I2), 
32.9 (CH2), 37.9 (GH2), 51.6 (CHN), 52.6 (CHN), 543 (GHN), 78.9 (COCH 20), 80.6 
(CH2Ph), , 126.1-135.4 (ArC), 156.1 (CONH), 160.2 (CONH), 168.5 (G02) 1  169.6 
(CO2)1172.0 (CO2)1 174.2 (CO2) and 199.5 (CO) 
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(N-a-benzyloxycarbonyl-glutamyi)(N-€-(2,4-dinitrophenyl)--lysyl )-(R)-trans-3-amino-4-
oxo-5-(2,6-dimethylbenzoyl)-pentanecarboxylic acid 18 
CQH 
O-kN jy N N 	 1 
0000"4, H 
0 	
H 0 A~6 
NO 
HN 
""d  NO2  
C39HN6015 Mw = 836.80 
(N-a-Benzyloxycarbonyl-glutamyl-lysyl)-(R)-frans-3-amino-4-oxo-5-(2,6-
dimethylbenzoyl)-pentanecarboxylic acid 17 (3.1 mg, 4.6 ptmole) was dissolved in dry 
dimethylformamide, and N-methylmorpholine and 2,4-dinitrofluorobenzene (1.0 mg, 5.1 
!xmole) were added. Upon completion, 12 hrs, the reaction mixture was taken into 
dichioromethane, washed with water, dried over magnesium sulphate and concentrated 
in vacuo to yield crude (N-a-benzyloxycarbonyl-glutamyI-N-*-(2,4-dinitrophenyI)-
Iysyl)-(R)-trans-3-amino4-oxo-5--(2,6-dimethylbenzoyl)-pentanecarboxylic acid 18 (2.9 
mg, 75%). 
RI (10010 MeOHJDCM) = 0.55 
MS (NOBA): MW 83730276 expected: 837.29441 
13 
C-NMR (CDCI3): 19.1 (2 x CR3), 21.5 (CI-12), 22.4 (CH2), 27.4 (CR2)1  29.0 (CR3), 
30.8 (CR2), 35.8 (CR2). 42.5 (CR2) 1  50.5 (CHN), 51.6 (CHN), 52.7 (Cl-IN), 78.9 
(COCH20), 79.2 (CH2Ph), 113.4 (CN02), 123.7 (CN02), 126.1-135.4 (ArC), 147.7 
(ArC) 156.1 (CONH), 160.2 (CONH), 170.6 (CO2)1171.1 (CO2)1 1713  (CO2)1 173 .6 
(G02) and 1995 (CO) 
ME 
Chapter 2 
2.4.4 N-a-Benzyloxycarbonglutamyl -Iysyl-aSp&tal 
General procedure for peptide synthesis under argon flow 
The substitution of the resin can be measured by spectrophotometric determination of 
Fmoc following treatment of a weighed sample with 20% piperidine in 
dimethylformamide. Loading: 10 x A(@absorption maximum, i.e. approx. 302nm) /9 x 
weight sample in mg (3 -4 mg) = mmole substitution / g resin. 
Structure determination can be achieved by gel carbon NMR. A NMR tube was filled 
with approximately 1 centimeter of dried resin (approx. 100 mg) and deuterated 
dichioromethane was added dropwise until the resin was fully swollen and 2 mm of 
solvent appeared in the bottom of the tube. 
N-cz-Fluorenylmethoxycarbonyl Weinreb amide resin 19 
OMe  H..~ap rL'oy 9 0 0 
The substitution of the resin was measured by spectrophotometic determination of Fmoc 
following treatment of a weighed sample with 20 010 piperidine in dimethylformamide 
and was found to be 032 mmole/g resin. 
13C-NMR Gel(CD,C1 2): 29.84 (NHCH,Ar), 34.02 (CH 2CONH), 45.51 (CH(Fmoc)), 
47.27 (N(OCH3)CH2), 62.23 (OCt-I3), 67.60 (CH20), 120.10, 125.16, 141.46 and 143.97 
(Ar), 156.72 (OCON(OCH 3) and 170.01 (CONH) 
WOT 
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Free amine Weinreb amide resin 20 
OM e 
N,,,OY--. 
N-a-Fluorenylmethoxycarbonyl Weinreb amide resin 19 (1.00 g, 0.52 mmole loading) 
was placed in glass tube with sintered disk, 5% piperidine in 
dichloromethane/dimethylformamide, 1:1 was added and the reactionmixture was mixed 
under an argon flow for 10 minutes. This treatment was followed by the application of 
20% piperidine in dimethylformarnide under an argon flow for 15 minutes. Upon 
completion the resin was washed (3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and 
dried in vacuo over potassium hydroxide. 
13C-NMR Gel(CD2C12): 29.68 (NHCH2Ar), 33.58 (CH2CONH), 47.77 (N(0(7H 3)CH2), 
61.68 (OCH3) and 171.64 (CONH) 
(N-a-fluorenylmethoxycarbonyl--O-tert-butyl-aspartyl)-Weinreb amide resin 21 
Free amine Weinreb amide resin 20 was placed in the glass tube and 25 ml 
dichioromethane was added. Subsequently FIATU (494 mg, 13 mmole, 2.5 eq), Fmoc-
Asp(O'Bu)OH (535 mg, 13 mmole, 25 eq) and DIPEA (0.45 ml, 336 mg, 2.6 mmole, 
5.0 eq) were added whilst mixing thoroughly under an argon flow. Upon completion, 
approximately 30 minutes, the resin was washed (3 x DCMIMeOH/DIPEA 17:2:1, 3 x 
DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried in vacuo over potassium 
61 
Chapter 2 
hydroxide. The substitution of the resin was measured by spectrophotometic 
determination of Fmoc following treatment of a weighed sample with 20 010 piperidine in 
dimethylformamide and was found to be 0.45 mmole/g resin. 
13C-NMR Gel(CD2Cl2): 27.97 (C(CHj3), 29.67 (NHCH2Ar), 34.07 (CH2CONH), 38.07 
(CH2CO21Bu), 45.68 (CH(Fmoc)), 47.29 (N(OCH3)CH2), 48.82 (NHCHCO), 61.67 
(0CH)1  67.01 (CH2O), 120.11, 125.28, 141.40 and 144.11 (Ar), 155.80 (OCON(OCH3), 
169.74 (CONH), 170.01 (OCONH) and 171.64 (CO2tBu) 
(N-(x-amino$-O-tert-butyl--aspartyl)-Weinreb amide resin 22 
COBu 
H2N f No OMe 
H 
0 ~~Y 
(N-a-F1uorenylmethoxycarbonyl--0-tert-buty1-asparty1)-Weinreb amide resin 21 was 
added to the glass peptide synthesis tube together with 20% piperidine in 
dimethylformamide (25 ml) and mixed vigorously under an argon atmosphere. Upon 
completion, approximately 30 minutes, the resin was washed (3 x DCMIMeOH/DIPEA 
17:2:1, 3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried in vacuo over 
potassium hydroxide. 
13C-NMR Gel(CD2Cl2): 28.03 (C(CH3)3) 1  29.64 (NHCH2Ar), 33.58 (CH2CO21Bu), 34.02 
(CH2CONH) 47.77 (N(OCH3)CH2), 48.72 (NHCHCO), 62.05 (OCH3), 155.80 
(OCON(OCH3) 1  169.74 (CONH), and 170.79 (CO21Bu) 
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(N-a-Fluoreny1methoxycarbonyl-N-*-tert-butoxycarbonyl-1ysyl)(1-O-tert-butyl-
aspartyl)-Weinreb amide resin 23 
)2tBu 
,OMe H 
N 	N,.., a4& 
0 
 
(N-a-amino--0-tert-butyl-asparty1)-Weinreb amide resin 22 was placed in the glass 
tube and 25 ml dimethylformamide was added. Subsequently PyBOP (468 mg, 0.90 
mmole, 2.5 eq), Fmoc-Lys(Boc)OH (422 mg, 0.90 mmole, 2.5 eq) and DIPEA (0.31 ml, 
233 mg, 1.80 mmole, 5.0 eq) were added whilst mixing thoroughly under an argon flow. 
Upon completion, after approximately 30 minutes, the resin was washed (3 x 
DCMJMeOH/DIPEA 17:2:1,3 x DCM, 2 x DMF, 2 x DCM and 2 x Me(I)H) and dried 
in vacuo over potassium hydroxide. Spectrophotometric determination of the 
substitution gave 0.40 mmole/g resin. 
13C-NMR Gel(CD2Cl2): 2234 (CH2CH2CH2NHBoc), 27.95 (C(CH1) Asp), 28.39 
(C(CH Lys), 29.67 (NHCH 2Ar), 29.69 (CH2CH2NFIBoc), 32.43 
(CH2CH2CH2CH2NHBoc) 33.59 (CH2CONH), 37.57 (CH,CO213u), 46.88 (CH2NHBoc), 
4734 (NHCHCO), 47.75 (N(OCH 3)CH2), 54.98 (NHCHCO), 61.70 (OCH3), 67.01 
(CH20), 120.09, 12531, 14139 and 144.08 (Ar), 156.23 (OCON(OCH 3 and CONH), 













asparty-Weinreb amide resin 23 was added to the glass peptide synthesis tube together 
with 20% piperidine in dimethylformainide (25 ml) and mixed vigorously under an 
argon atmosphere. Upon completion, approximately 30 minutes, the resin was washed (3 
xDCM/MeOH/DIPEA 17:2:1,3 xDCM, 2 x DMF, 2xDCM and 2 xMeOH)and dried 
in vacuo over potassium hydroxide. 
13 
C-NMR Gel(CD2C12): 22.85 (CH2CH,CI-L,NHBoc), 28.00 (C(CH 3)3 Asp), 2837 
(C(CH3 )3 Lys), 29.99 (CH2C1-I2NHB0c), 32.43 (CH2CH2CH2CH2NHB0C) 34.00 
(CH2CONH), 38.00 (CH2CO.,'Bu), 46.88 (CH-,NHBoc), 47.34 (NHCHCO), 47.75 
(N(OCH3)CH2)
1 
 54.98 (NHCHCO), 61.70 (OCHJ, 15830 (OCON(OCH3 and CONH), 
and 171.5 (CO,Bu and N1-ICO243u) 
(Na-Benzyloxycarbony1-y-O-tert-butyl-glutamY1)(N-E-tert-bUtOXYCarbOflYl-lYSYl)( -O-
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(N-a-Amino-N-E-tert-butoxycarbonyl-lysyl)(5-O-tert-buty1-aspartyl)-Weinreb amide 
resin 24 was placed in the glass tube and 25 ml dimethyllormamide was added. 
Subsequently PyBOP (520 mg, 1.00 mmole, 2.5 eq), Z-Glu((YBu)OH (337 mg, 1.00 
mmole, 2.5 eq) and DIPEA (035 ml, 259 mg, 2.00 mmole, 5.0 eq) were added whilst 
mixing thoroughly under an argon flow. Upon completion, approximately 30 minutes, 
the resin was washed (3 x DCMIMeOHJDIPEA 17:2:1, 3 x DCM, 2 x DMF, 2 x DCM 
and 2 x MeOH) and dried in vacuo over potassium hydroxide. 
13C-NMR Gel(CD2Cl2): 22.40 (CH,CH,CH2NHBoc), 27.98 (C(CH3 )3 Asp and Glu), 
2838 (C(CH3)3 Lys), 29.50 (CH,CH2NHBoc), 31.76 (CH2CH2CH2CH2NHBoc) 33.58 
(CH2CONH), 37.57 (CH2CO2tBu), 46.88 (CH2NHBoc), 4734 (NHCHCO), 47.76 
(N(OCH3)CH2), (NHCHCO and NHCHCO) , 62.05 (OCH3), 66.98 (CH,O), 79.80 
(C(CH3)3 Lys), 80.88(C(CH3)3 Glu), 81.50 (C(CH3)3 Asp), 128.12 and 145.26 (Ar), 






o yY yH 
V 0 
N HBoc 
C31H 18N4O9 Mw = 620.75 
(N-a-Benzyloxycarbonyl-y-O-:ert-buty1-gIutamyl)(N--tert-butoxycarbonyl-1ysyl)(-O-
tert-butyl-aspartyl)-Weinreb amide resin 25 was placed in the glass peptide synthesis 
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tube and anhydrous tetrahydrofuran (25 ml) was added. Whilst mixing thoroughly, 
lithium aluminium hydride (76 mg, 2.00 mmole) was added in small portions. Upon 
completion of the reaction after 30 minutes, the organic layer was collected. The 
tetrahydrofuran layer was subsequently washed with potassium hydrogen sulfate (3x), 
sodium hydrogen carbonate (3x) and brine (3x), dried over magnesiumsulfate, and 
concentrated in vacuo, to yield 26 (10 mg, 16.1 itmole). 
13C-NMR (CDCI 3): 22.19(CH2CH2CH.,NHBoc), 27.00 (CH2CH2CH2CH2NHB0C) 27.88 
(C(CH3)3 Asp and Glu), 2838 (C(CH3)3 Lys), 29.17 (C,CHCO 2tBu) 31.47 
(CFI2CH2NHBoc), 31.88 (CH 2CO2tBu Glu), 36.65 (CH 2CO2tBu), 40.04 (CH,NHBoc), 
48.79 (NHCHCO Asp), 52.89 (NHCHCO Lys) 54.28 (NHCHCO Glu), 66.98 (CH 20), 
79.29 (C(Cl-Lj 3 Lys), 80.84(C(CH 3)3 Glu), 81.77 (C(CH3)3 Asp) 127.89, 12834, and 
136.06 Ar), 156.18 (CONH and CONH), 17031 (NHCO 2CH2Ar and NHCO2Bu) 171.66 





oAN4 iNX rH 
0/ 0 
NH 2 
C 1 H 214409 MW= 508.53 
(N-a-Benzyloxycarbonyl -y-Ote,i-butyl-gIutamy1)(N-E-tert-butoxycarbonyl-lySyl)(-O-
tert-butyl-aspartal 26 (10 mg, 16.1 tmole) was treated with 25% trifluoroacetic acid in 
dichioromethane with a catalytic amount of water. The reaction mixture was 
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concentrated in vacuo to yield N-a-Benzyloxycarbonyl-glutamyl-lysyl-aspartal 27 (7.6 
mg, 15.9 [tmole) in a 93% yield. 
13C-NMR (CDCI3): 22.19(C1-I2CH1CH,NH,), 27.00 (CH,CFL,CFL,CH 2NH,), 29.17 
(CH2CH2CO,H) 31.47 (CH2CH2NH,), 31.88 (CH2CO.,H), 36.65 (CH2CO2H), 40.04 
(CH2NH2), 48.79 (NHCHCO), 52.89 (NHCHCO) 54.28 (NHCHCO), 66.98 (CH 20), 
127.89, 12834, and 136.06 Ar), 156.18 (CONH and CONH), 17031 (NHCO 2CFI2Ar 






gOyN "A N 	
H 
CO2tBu 
0 ro;;~~ 	0 	0 
(N-a-amino--O-tert-butyl-aspartyl)-Weinreb amide resin 22 was placed in the glass 
tube and 25 ml dimethylformamide was added. Subsequently PyBOP (585 mg, 1.13 
mmole, 2.5 eq), Fmoc-lle-OH (399 mg, 1.13 mmole, 2.5 eq) and DIPEA (039 ml, 291 
mg, 2.25 mmole, 5.0 eq) were added whilst mixing thoroughly under an argon flow. 
Upon completion, approximately 30 minutes, the resin was washed (3 x 
DCM/MeOWDIPEA 17:2:1,3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried 
in vacuo over potassium hydroxide. Spectrophotometic determination of the substitution 
gave 038 mmole/g resin. 
13C-NMR Gel(CD2C1 2): 11.79 (CHCHICH3), 15.75 (CHCI-13), 25.19 (CHCH2CH3), 28.26 
(C(CH3)3), 29.67 (NHCH,Ar), 34.31 (CH2CONH), 3830 (CH2CO1tBu), 47.74 
(N(OCH3)CH,), 49.20 (N1-ICHCO Asp), 60.11 (NHCHCO lie), 62.52 (OCR,), 67.37 
(CH20), 81.91 (C(CH3)3), 120.50, 125.72, 141.84 and 144.54 (Ar), 156.82 
(OCON(OCI-11) and 17151-175.52 (CONH, CONH, OCONH and CO,tBu) 
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(Na-Amino-isoleucinyl)(-O-tert-butyl-aspartyl)-Weinreb amide resin 29 
CO21Bu 
H2N(NZ yXO'  
(N-a-Huorenylmethoxycarbonyi-isoleucinyl)(1-O-tert-buty1-aspartyl)-Weinreb amide 
resin 28 was added to the glass peptide synthesis tube together with 20 01b piperidine in 
dimethyllormamide (25 ml) and mixed vigorously under an argon atmosphere. Upon 
completion, approximately 30 minutes, the resin was washed (3 x DCM/MeOH/DIPEA 
17:2:1, 3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried in vacuo over 
potassium hydroxide. 
13C-NMR Gel(CD2C12): 12.28 (CHCH20H3), 1638 (CHCH3), 2430 (CHCH2CH3), 2831 
(C(CH3)3), 34.66 (CH2CONH), 38.47 (CH2CO2tBu), 47.00 (N(OCH1)CH2), 49.20 
(NHCHCO Asp), 6036 (NHCHCO lie), 62.52 (OCH3), 81.85 (C(CH3)3), 156.82 
(OCON(OCH3) and 171.08-1754.61 (CONH, CONH and CO2tBu) 
(N-u-Fluorenylmethoxycarbonyi-y-O-tert-butyl-glutamyl)(isoleucinyi )(-O-tert-butyl-
aspartyl)-Weinreb amide resin 30 
CO2tBu 
9 	- , 
.2 




(N-a-Amino-isoleucmyi)(-O-tert-butyl-aspartyl)-Weinreb amide resin 29 was placed in 
the glass tube and 25 ml dimethylformamide was added. Subsequently PyBOP (494 mg, 
M. 
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0.95 mmole, 2.5 eq), Fmoc-Glu(OtBu)-OH (404 mg, 0.95 mmole, 2.5 eq) and DIPEA 
(033 ml, 246 mg, 1.9 mmole, 5.0 eq) were added whilst mixing thoroughly under an 
argon flow. Upon completion, approximately 30 minutes, the resin was washed (3 x 
DCM/MeOWDIPEA 17:2:1,3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried 
in vacuo over potassium hydroxide. Spectrophotometic determination of the substitution 
gave 032 mmole/g resin. 
13C-NMR Gel(GD2Cl2): 1231 (HCI-l2CHj, 1638 (CHCH3), 2430 (CHCH2CH), 2835 
(2 x C(CH3)1), 32.22 (CH2CH2CO2tBu) 34.49 (CH2CONH), 38.71 (CHCH2CO2tBu), 
47.02 (NHCHCO Glu), 47.68 (N(OCHJCH2), 6039 (NHCHCO Ile), 6239 (OCR,), 
67.62 (CH20), 81.74 (C(CH 3 )1 Asp),8332 (C(CH1)3 Glu), 120.56, 125.81, 141.84 and 
144.65 (Ar), 157.13 (OCON(OCH 3) and 170.99-175.52-181.00 (CONH, CONH, 
CONE, OCONH, CO2tBu Asp and CO2tBu Glu) 
amide resin 31 
CO2IBu 
CO1Bu 




aspartyl)-Weinreb amide resin 30 was added to the glass peptide synthesis tube together 
with 20% piperidine in dimethylformamide (25 ml) and mixed vigorously under an 
argon atmosphere. Upon completion, approximately 30 minutes, the resin was washed (3 
x DCM/MeOWDIPEA 17:2:1,3 x DCM, 2 x DMF, 2 x DCM and 2 x MeOH) and dried 
in vacuc over potassium hydroxide. 
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13C-NMR Gel(CD2C12 ): 1231 (CHCH2CH1)1  16.41 (CHCH1), 2430 (CHCH,CH3), 2835 
(2 x C(CHj3), 30.76 (CH.,CH2CO2tBu), 32.45 (CH2CH2CO2tBu) 34.49 (CH2CONH), 
37.93 (CHCH2CO2tBu), 47.68 (N(00H 3)CI-L,), 5534 (NHCHCO Asp), 57.93 
(Nl-ICHCO Glu), 60.39 (NHCHCO lie), 62.57 (OCH 3), 8135 (C(CH3)3 Asp),81.88 
(C(CH3)3 Glu), 120.56, 125.81, 141.84 and 144.65 (Ar), 157.13 (OCON(OCH3) and 
17131-173.17 (CONH, CONH, CONH, CO 2 Bu Asp and CO2 Bu Glu) 
(N-a-FIuoreny1methoxycarbonyl-vaiinyiy-O-:err-butyl-glutamylXiso1eucinyi)( -O-





amide resin 31 was placed in the glass tube and 25 ml dimethylformamide was added. 
Subsequently PyBOP (416 mg, 0.80 mmole, 2.5 eq), Fmoc-Val-OH (272 mg, 0.80 
mmole, 2.5 eq) and DIPEA (0.28 ml, 207 mg, 1.60 mmole, 5.0 eq) were added whilst 
mixing thoroughly under an argon flow. Upon completion, approximately 30 minutes, 
the resin was washed (3 x DCM/MeOHIDIPEA 17:2:1,3 x DCM, 2 x DMF, 2 x DCM 
and 2 x MeOH) and dried in vacuo over potassium hydroxide. Spectrophotometic 
determination of the substitution gave 0.25 mmoleig resin. 
13C-NMR Gei(CD2Cl2): 11 (.97CHCH2CH3), 16.10 (CHCH3), 19.65 (CH(CH3),), 23.94 
(CHCH2CH3), 27.96 (2 x C(CH3)3), 30.99 (CH2CH,CO21Bu), 33.61 (CH2CH2CO21Bu) 
34.40 (CH,CONH), 37.55 (CH(CH 3)2), 3831 (CHCH2CO2113u), 46.61 (N(OCH3)CH2), 
55.40 (NHCHCO Asp), 57.49 (NHCHCO Glu), 59.98 (NHCHCO Val), 60.40 
(N1-ICHCO lie), 62.04 (OCt-I3), 67.50 (CHIO), 81.27 (C(CH3)3 Asp),81.70 (C(CH3 )3 
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Glu), 120.56, 125.78, 141.65 and 145.02 (Ar), 157.13 (OCON(OCH 3) and 17131-
173.17 (CONH, CONH, CONH, CONH, CO2tBu Asp and CO2tBu Glu) 




(4.. 0 	0 
(NaFluorenylmethoxycarbonyl-valinyI)(y-O-tert-butyl-glutamy1)(isoleUCiflYlX(-O-
:ert-butyl-aspartyl)--Weinreb amide resin 32 was added to the glass peptide synthesis 
tube together with 20% piperidine in dimethylformamide (25 ml) and mixed vigorously 
under an argon atmosphere. Upon completion, approximately 30 minutes, the resin was 
washed (3 x DCM/MeOHIDIPEA 17:2:1, 3 x DCM, 2 x DMF, 2 x DCM and 2 x 
MeOH) and dried in vacuo over potassium hydroxide. 
13 
C-NMR Gel(CD2Cl2): 11 (.97CHCH2CH3), 16.10 (CHCH), 19.65 (CH(C143)2), 23.94 
(CHCH2CH3), 27.96 (2 x C(Cl-I,) .,), 30.99 (CH2CH2CO21Bu), 33.61 (CH1CI-l2CO2tBu) 
34.40 (CH2CONH), 37.55 (CH(CH3)2), 3831 (CHCI-12CO3tBu), 46.61 (N(OCH3)C1-12), 
55.40 (NHCHCO Asp), 57.49 (NHCHCO Glu), 59.98 (NHCHCO Val), 60.40 
(NHCHCO Ile), 62.04 (OCR,), 81.27 (C(CH 3)3 Asp),81.70 (C(CH3) Glu), 157.13 
(OCON(OCH3) and 171.31-173.17 (CONH, CONH, CONH, CONH, CO2 Bu Asp and 
CO2tBu Glu) 
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(N-a-Amino-valinyl)(y-O-zerr-butyl-glutamylXisoleucinyl )-O-terr-butyl-aspartal 34 
COIBu 
0 	






CHN4O9 Mw = 570.73 
(N-a-amino-va1inyl)(y-O-terr-butyl-g1utamyl)(iso1eucinyl)(-O-tert-butyl-aspartyl)-
Weinreb amide resin 33 was placed in the glass peptide synthesis tube and anhydrous 
tetrahydrofuran (25 ml) was added. Whilst mixing thoroughly, lithiumaluminium 
hydride (47 mg, 1.25 mmole) was added in small portions. Upon completion of the 
reaction after 30 minutes, the organic layer was collected. The tetrahydrofuran layer was 
subsequently washed with potassiumhydrogensulfate (3x), sodiumhydrogencarbonate 
(3x) and brine (3x), dried over magnesiumsulfate, and concentrated in vacuo, to yield 34 
(8 mg, 14 itmole). 
13C-NMR (CDCI 3): 11.97 (CHCH2CH3), 16.10 (CHCH), 19.65 (CH(CH3 )2), 23.94 
(CHCH2CH3), 27.96 (2 x C(CH3)3), 30.99 (CH2CH2CO71Bu), 33.61 (CH2CH2CO2tBu) 
37.55 (CH(CH3)), 3831 (CHCH2CO21Bu), 5540 (N1-ICHCO Asp), 57.49 (NHCHCO 
Glu), 59.98 (NHCHCO Val), 60.40 (NHCHCO lie), 81.27 (C(CH 3 )3 Asp),81.70 
(C(CH3)3 Glu), 17131-173.17 (CONH, CONH, CONH, CO2tBu Asp and CO2tBu Glu) 












CFIN4O8 Mw = 458.53 
(N-aAmino-valinyl)(y-O-tert-buty1-g1utamy1Xisoleuciny1)-O-tert-buty1-asparta1 	34 
(8.0 mg, 14.0 imole) was treated with 25% tiifluoroacetic acid in dichioromethane with 
a catalytic amount of water. The reaction mixture was concentrated in vacuo to (N-a-
Amino-valinyl-glutamyl-isoleucinyl-aspartal 35(6.1 mg, 133 .tmo1e) in a 950/0 yield. 
13C-NMR (CDC1 3): 11.96 (CHCH2CH3), 16.10 (CHCH3), 19.65 (CH(CH), 23.94 
(CHCH2CH3), 30.99 (CH2CH2CO2H), 33.61 (CH2CH2CO2H) 37.55 (CH(CH3)2), 3831 
(CHCH2CO2H), 55.40 (NHC1-ICO), 57.49 (NHCHCO), 59.98 (NHCHCO), 60.40 
(NHCHCO), 17131-173.17 (CONH, CONH, CONH, CO 2H and CO2H) and 201.69 
(CHO) 
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Chapter 3 Affinity Purification of Caspases 
3.1 Introduction 
Affinity chromatography is a type of adsorption chromatography in which the 
molecule to be purified is specifically and reversibly adsorbed by a complementary 
binding substance (ligand) immobilised on an insoluble support (matrix). Purification is 
often in the order of several thousand-fold and recoveries of active material are generally 
very high. The separation can be achieved in a single step, allowing immense time 
saving over less selective multi-stage procedures. Furthermore, affinity chromatography 
has a concentrating effect, which enables large volumes to be conveniently processed. 
The high selectivities of the separations derive from the natural specificities of the 
interacting molecules. Therefore affinity chromatography can be used to purify small 
amounts of biological material from large amounts of contaminating substances. 
Early work involving avidin-biotin chemistry centred around biotin's function as 
a vitamin. In 1927, rats fed large quantities of egg white developed dermatitis, indicating 
malnutrition 12441. Supplementation of the diet with vitamin H, which was identified as 
the biotin structure in 1940 [245, 2461, prevented this dermatitis. The malnutrition was 
eventually attributed to the depletion of biotin. Avidin, a protein present in the egg 
white, was complexing with the vitamin and thus interfering with the animal's nutrition. 
As early as 1941, the extraordinary affinity of avidin for biotin was recognised [247]. 
The crystallisation of avidin 12481, and the chemical synthesis of biotin [249], eventually 
led to the use of avidin-biotin technology as a research tool. Becker and Wilchek 
coupled biotin to bacteriophages for diagnostic purposes [250]. Heitzmarm and Richards 
used the avidin-biotin interaction as an affinity cytochemical probe [2511. In 1976 
Bayer, Wilchek and Skuteisky used biotinylated lectins and biotinylated antibodies to 
localise receptors and antigens on erythrocyte membranes [252], and introduced the term 
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affinity cytochemistry. The avidin-biotin interaction has since become increasingly 
popular for a variety of specific applications and technologies. 
Affinity purification has been accomplished using the avidin-biotin complex. A 
ligand with affinity for the protein of interest is labelled with biotin and incubated with 
the protein in a crude mixture. To isolate the protein of interest, the crude mixture is 
passed through an immobilised avidin or streptavidin column, which will bind the 
biotinylated ligand. Theoretically, the biotinylated ligand-protein complex can be eluted 
from the avidin column by using an excess of free biotin. However, this method is 
extremely inefficient due to the strong interaction between avidin and biotin. 
This chapter describes a method derived for the affinity purification of active 
caspases from apoptotic cytosolic chicken DU249 (S/M extracts) through avidin using a 
biotinylated probe. 
3.2 Results and Discussion 
3.2.1 preparation extracts 
Current understanding of caspase function has been facilitated by the 
development of cell-free systems for the study of apoptosis [11, 253-2581. One such 
system uses extracts from DU249 chicken hepatoma cells that become committed to 
apoptosis after perturbation of the cell cycle [11]. Highly concentrated cytosolic extracts 
from these morphologically normal cells (S/M extracts) reproduce all of the biochemical 
features of apoptosis in substrate nuclei. The entire programme of apoptotic events is 
inhibited by caspase inhibitors 1121,  just as in intact cells. 
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The apoptotic pathway can be conceptually divided into at least three stages (Fig 
3. 1A). In response to an apoptotic insult, cells enter a "condemned" phase, in which the 
apoptotic program has been initiated, but cells can be rescued by various survival 
factors. Once cells pass a point of no return, they are in the "committed" phase and can 
no longer be rescued [2591. During both these phases, the cells appear morphologically 
normal. Eventually, committed cells undergo an abrupt transition into the "execution" 
phase, during which cellular disassembly and death occur. 
	
I 	 I 
A 	condemned 	 committed 	I Point of 
Insult No Return 
V JIM- V 	tk.I/ 
no rescue possible 	morphological changes rescue by survival factors 	 caspases activated i downstream factors 
activated 
C/i) extract 	 S/M extract 	 E/X extract 
B 	+ aphidicolin release + nocodazole 
12 hr 6 h 3 h 
jow- 
0 	 5 h 	10 hr 15 hr 20 hr 
Fig 3.1 Preparation of apoptotic extracts 
Adapted from Samejima et aL 12601. 
(A) Diagram of apoptosis as a three stage process (B) Protocol used for harvesting samples for 
examination of caspase activation 
Studies in our laboratory of chicken DU249 cells at various times alter 
subjecting cultures to a synchronisation protocol (Fig 3.IB), shown previously to induce 
an apoptotic response in this cell line [II], provided a reliable protocol for the 
preparation of extracts from the three apoptotic stages [260]. Treatment of chicken 
DU249 cells with aphidicolin blocked them in S phase. The floating cells then harvested 
after a change of medium and a 2h treatment with nocodazole to induce a mitotic block 
IL 
Chapter 3 
were predominantly (>60%) mitotic, with only 10-20 010 of apoptotic cells. Despite the 
normal appearance of the vast majority of these cells, extracts prepared from them 
contained high levels of active caspases, as detected with the affinity labelling reagent 
Z-EK(biotin)D-aomk [2611. Because these cells are destined to rapidly undergo 
apoptosis if left in culture it has been postulated that SIM extracts reproduce events from 
the committed stage of apoptosis [2601. Due to their high active caspase content, S/M 
extracts provide a useful cytosol for the affinity purification of active caspases from 
chicken DU249 cells. 
3.2.2 affinity chromatography results and discussion 
To enable the affinity purification of caspases using avidin-biotin technology, the 
active caspases in apoptotic cytosolic chicken DU249 SIM extracts were labelled with 
the affinity probe Z-EK(biotin)-D-aomk. The covalently bound caspase inhibitor thus 
served as an affinity ligand for the avidin column. The active site of a caspase is buried 
within a cleft (see X-ray structures Fig. 1.6), and thus the biotin label from the affinity 
probe is not readily available. Therefore, the caspases in the extract had to be denatured 
in order to enable the biotin ligand to bind to the avidin immobilised on the agarose 
beads. Several immobilised avidin columns were investigated, such as avidin, 
monomeric avidin, avidin bound to agarose beads via a linker arm, streptavidin, and 
combinations thereof. 
The strong avidin-biotin affinity, which is its major benefit in affinity 
chromatography, also proved to be a major drawback. Using immobilised avidin beads, 
caspases could only be recovered under strongly denaturing conditions, contaminating 
the fractions with stripped avidin monomers and enabling only low recovery. Avidin 
bound to agarose via a linker molecule did not show any improvements over the 
previous method. The use of monomeric avidin beads greatly improved the recovery of 
W. 
Affinity Purification of Caspases 
the caspase fraction from the column, but showed a decrease in purity of the fraction 
(see Fig 3.2). When a second round of affinity chromatography over streptavidin beads 
was conducted a virtually pure caspase fraction was obtained (see Fig 33). Streptavidin 
has the advantage over avidin that less non-specific binding occurs due to its lower p1. A 
drawback is the lower recovery of protein than occurs with monomeric avidin. It was 
found that a combination of first affinity chromatography over monomeric avidin 
followed by a purification round over streptavidin beads results in the highest 
purification and greatest recovery of the caspases. 
 












Figure 3.2 Affinity purification over monomeric avidin 
Affinity chromatography of cytosolic chicken DU249 S/M extract over immobilised monomeric avidin, 
the caspase fraction (boxed) starts to elute in the final wash. A high recovery of caspases was achieved 
using this protocol. 
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Figure 3.3 Affinity purification over streptavidin 
Affinity chromatography of the monomeric avidin chromatography concentrated fraction over 
immobilised streptavidin, the caspase fraction (boxed) elutes virtually pure. 
Evaluation of several affinity chromatographic methods using immobilised 
avidin variants revealed the following: while none of the methods alone can furnish both 
sufficient recovery and purity of the caspase fraction, a combination of immobilised 
monomeric avidin and streptavidin does. Although these results represent preliminary 
studies on a small scale we believe that the affinity chromatography of affinity labelled 
caspases over avidin will provide the means to isolate larger amounts of caspases from 
apoptotic extracts. 
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3.3 Materials and methods 
33.1 Preparation of S/T4 extracts 
From adherent culture 
Day 1 (evening) 
Have subconfluent DU249 cells in a T75 flask 
Split the cells into 12 X T150 flasks 
Add 45 ml pre-warmed medium (10 010 FBS-RPMI) 
Culture for Ca. 48 hours in the CO., incubator until the cells are up to 60% confluent 
Day 3 (evening) 
aphidicolin treatment 
Pre-warm medium (10010 FBS-RPMI) 
Thaw, vortex, and spin down aphidicolin stock solution (10 mg/ml) 
Add 100 jil aphidicolin stock solution to 500 ml medium (final conc. 2 ug/ml) 
Decant medium from T150 flasks into waste, let the flasks stand in a queue 
Add 45 ml of aphidicolin/medium to each culture flask, bathing side of flask to which 
the cells are attached 
Culture for 10-12 hours in the CO2 incubator 
Day 4 (early morning) 
release from aphidicolin 
Pre-warm medium and RPM! 
Tap a side of the T150 flasks 5 times to remove loosely attached cells, and decant 
medium 
Add 10 ml pre-warmed RPM!, let it flow 3 times from front to back and side to side 
and decant 
Add 45 ml pre-warmed fresh medium to each flask 
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Culture for 6 hours in the CO 2 incubator 
Nocodazole treatment (microtubule depolymerizing drug) 
Thaw, vortex, and spin down nocodazole stock solution (1 mg/ml) 
Add 50pI stock solution to 500 ml medium (final conc. lOOng/mi) 
Add 45 ml nocodazole/medium to each culture flask, bathing side of flask to which 
the cells are attached 
Incubate for 2-4 hours in CO 2 incubator until >509o' cells are mitotic (rounded up) 
Look at the cells every hour by inverted microscope. Even if the cells are <50% mitotic 
after 4 hours, do not incubate any longer. 
Harvesting of the cells 
Cool Beckman J2-21 and Heraeus Biofuge to 4°C 
Make incomplete KPM buffer 
To harvest mitotic cells tap two sides of T150 flask 10 times each and recover 
detached cells into centrifuge bottles 
Spin at 2000 rpm (614 x g) for 5 min at 4°C (Beckman J2-21, JA-14 rotor) 
Aspirate supernatant and resuspend pellet in 20 ml incomplete KPM gently using a 
25 ml plastic pipet with a large bore so as not to damage mitotic cells, transfer into 50 ml 
tube, and add incomplete KPM up to 50 ml 
Spin at 13000 rpm (13,793 x g) for 5 min at 4°C (Heraeus Biofuge) 
Make complete KPM buffer 
Aspirate supernatant and resuspend pellet in 2 ml complete KPM gently using I ml 
Pipetman, and add complete KPM up to 40 ml 
Spin at 13000 rpm for 5 min at 4°C (Heraeus Biofuge) 
Aspirate supernatant and resuspend pellet with 1 ml complete KPM and transfer to 
grinder (Medium (KONTES 20, capacity I ml) or Large (KONTES 21, capacity 3 ml) 
size depending on volume) 
Aspirate supernatant and freeze in isopropanol slush chilled at -80 °C 
Store at -80 °C (Cell pellets can be stored for months without problems) 
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Preparation of apoptotic cell extract 
Work on ice! 
Thaw the cell pellet (which should be in buffer containing protease inhibitors) and 
lyse by 3 cycles of thawing rapidly at 37 °C (leave until the pellet is just thawed, not 
longer) and freezing again in isopropanol slush chilled at - 80°C 
Sonicate on ice: 30 sec. by 10 sec. pulse and 10 sec interval, medium setting 
Ultracentrifuge: 2 h, 60K to 75 K rpm for 2 h (put mineral oil on top of each tube) 
Recover clear extract between pellet and mineral oil 
Spin at 13000 rpm (13,793 x g) for 10 min at 4°C (Heraeus Biofuge) 
Recover clear supernatant. Measure protein concentration on 1 jil 
Aliquot and freeze in liquid nitrogen 
Store at -80°C (extracts are stable for months at - 80°C) 
3.3.2 Labelling of active caspases 
Labelling of caspases 
To 100 IAI apoptotic extract add 1 tl Z-EK(biotin)D-aomk (100 IAM stock) 
Label for 15 min at 37°C 
Removal excess labelling reagent 
Load onto Sephadex G25 medium column 
Denature protein lysate by adding 1 volume of denaturing buffer 
Boil for 5 min 
Add 4 volumes of correction buffer 
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3.3.3 Avidin purification 
Wash avidin-agarose with MDB 2 times (Ca. 1 volume resin for 1 volume of sample) 
Add protein sample 
Incubate at 40  C for 1 hour whilst rotating 
Spin down resin at 13000 rpm (13,793 x g) for 1-2 mm (Heraeus Biofuge) 
Remove supernatant 
Wash 3 times with I ml washing buffer, then once with final washing buffer 
Elute protein 
Take aliquot and add 100 jsl 1X sample buffer 
Boil for S mm 
Spin down and keep supernatant (Can be repeated) 
Load the samples on SDS-PAGE 
3.3.4 Western Blotting 
Put plastic holder in tray with transfer buffer with its dark side down 
Put I ECL pad in 
Add 2 sheets of Whatman paper 
Remove air-bubbles by gently rubbing with plastic pipette 
Transfer gel with the aid of 1 damp Whatman paper 
Add nitrocellulose membrane 
Add 2 sheets of Whatman paper 
Remove air-bubbles by gently rubbing with plastic pipette 
Add another ECL pad 
Remove air-bubbles by gently rubbing with plastic pipette 
Close plastic holder and transfer into immunoblotting tank put tank in cold room 
Transfer proteins under 55V and max current for approx. 3 hours 
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Stain with Ponceau S red for 20 mm. 
Wash briefly with PBS 
Puncture holes in membrane to indicate position of protein marker bands 
Wash repeatedly until Ponceau red has disappeared 
After transfer rinse with PBS Tween (0.1%) 2 X 5 mm. 
Block with 5% milk powder in PBS Tween for 40 min at 4°C 
Rinse with PBS 3 X 5-10 mm 
Label with streptavidin-horseradish peroxidase conjugate (3 pL per 10 ml PBS) for 
3 hours at 4°C 
Rinse with PBS 3 X 5-10min  
Activate with ECL solutions (1:1) 
Keep slightly moist and wrap in cling film 
Put in photographic box 
Expose film at time interval (1,3,5, 10 min and overnight) 
3.3.5 Solutions 
Incomplete KPM buffer(100,nl) 
Stock Volume Final concentration 
KCI 2M 2.5m1 50 m 
PIPES pH 7.0 1 M 5.0 ml 50 mM 
EGTA 0.5 M 2.0 ml 10 MM 
MgCl2 2 M 96 jsl 1.92 mM 
DdH20 90.5 ml 
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Complete KPM buffer (50 ml) 
Stock Volume Final concentration 
Incomplete KPM 50 ml 
Cytochalasin B 20 mM 50 ul 20 pM 
CLAP 1000X 50 y IX 
PMSF 0.IM 50p1 100 Jim 
Dli' 1M 50 p1 1mM 
Denaturing buffer (2X) (10 ml) 
stock Volume Final concentration 
SDS 20% 500 p1 0.5010 
PIPES pH 7.0 1M 200 p1 10 mm 
-mercaptoethano1 2 nil 1 X 
DdH20 73 ml 
Correction buffer (10 ml) 
Stock Volume Final concentration 
Nonidet P40 12.5% 1 ml 1% 
Na deoxycholate 12.5% 1 ml 1% 
EDTA 0.5 M 40 lit 1.6 mM 
PIPES pH 7.0 1 M 125141 10 mM 
DdH20 7.84 ml 
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Mitotic Dilution Buffer (MOB) (10 ml) 
Stock Volume Final concentration 
NaCl 2M 50mM 
PIPES pH7.0 IM 50mM 
EGTA 0.5M 5 m 
MgCl2 2M 2 m 
DTF 1M 1mM 
Washing buffer 
Dilute Denaturing buffer 1:2 in MDB 
Add 4 vol of correction buffer 
Final washing buffer (10 ml) 
Stock Volume Final concentration 
PIPES pH 7.0 1 M 100 jsl 10 mM 
EDTA 0.5 M 32 j1 1.6 mM 
-mercaptoethanol 1 ml 1X 
1h1420 8.87 ml 
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Stock solutions 
Compound Concentration Weight volume Solvent Store 
Aphidicolin 10 mg/mi 10 mg 1 ml DMSO -20 °C 
Nocodazole 1 mg/ml I mg 1 ml DMSO -20 °C 
Cytochalasin B 20 mM 10 mg 1.04 ml DMSO -20 °C 
DTI' I M 154.2 mg 1 ml DdH20 -20 °C 
1000 X CLAP 1 mg each/ml 1 mg each 1 ml DMSO -20 °C 
PMSF 0.1 M 17.4 mg 1 ml DMSO -20 °C 
KCI 2 M 14.91 g 100 ml ddH20 r.t. 
PIPES 1 M 30.24 g 100 ml ddH20 r.t. 
EGTA 0.5 M 19.02 g 100 ml ddH20 r.t. 
MgCl, 2 M 40.66 100 ml ddH20 r.t. 
Nonidet P40 12.5% 12.5 g 100 ml ddH20 r.t. 
Na deoxychiolate 12.5% 12.5 g 100 ml ddH20 r.t. 
EDTA 0.5 M 16.81 g 100 ml ddH20 r.t. 
NaCl 2 M 11.69 g 100 ml ddH20 r.t. 
Chapter 4 Identification of Caspases by 213-PAGE 
4.1 Introduction 
Many key aspects of protein biology are not encoded at the genetic level and can 
only be ascertained by protein-level analysis. These include the specific localisation of a 
protein within the cell, the proteins with which it interacts, and modifications, such as 
phosphorylation and glycosylation, which are central to the activation and function of 
the protein. Furthermore, protein expression is not necessarily inferred through the 
presence of its mRNA. Transcript levels do not always have a tight correlation with 
protein levels [262]. Therefore, the expression of a gene has no definitive relationship to 
the ultimate expression or abundance of its protein product. The lack of correlation can 
be attributed to: a) temporal differences between gene expression and actual protein 
expression; b) spatial differences between the site of gene expression and where the 
protein products act; c) differential stability and turnover of mRNA versus protein 
product and d) post-transcriptional splicing of the mRNA to yield various protein 
products. Proteomics, the analysis of total gene expression at the protein level, provides 
a formidable tool for studying biological systems and understanding the relationship 
between various expressed genes and gene products. The technology for performing 
proteome studies has been available for almost 25 years, even though the term 
proteomics is relatively new [2631. At the core of proteomics is two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) [264, 2651. This technique is capable of 
resolving up to 11,200 proteins and peptides from a single, complex mixture in a single 
experiment [2661. Subsequently the individual peptides and proteins can be further 
characterised using amino acid analysis, amino-terminal or internal amino acid 
sequencing, and mass spectrometry [2671. Figure 4.1 shows the main steps involved in 
proteomic analysis. This ability to characterise the genetic basis of changes of proteins 
of interest provides a vital link between gene information at the DNA level (genomics) 
and observed phenotypic differences at the system level (functional genomics). Thus, 
with the progress of the Human Genome Project and other DNA sequencing programs, 
proteomics promises to be an increasingly important field of study. 
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Figure 4.1 Steps Involved in analysing a biological sample by proteomics 
An outline of the steps involved in characterising a biological problem by mass spectrometry. Cells are 
grown and treated with the model compound whose impact is to be studied. Cell lysates from stimulated 
and unstimulated cells are then processed in parallel. Typically, these lysates are then subjected to an 
affinity based enrichment step followed by electrophoresis and silver staining. The bands or spots of 
interest are excised and submitted for mass spectrometric analysis. These are then digested with trypsin 
followed by analysis of a fraction of the digested material by MALI)1 MS as a screening method. The 
masses of the tryptic peptides are used to search a theoretical digest of all the known proteins in sequence 
databases. If further analysis is required, the remainder of the digested material is desalted on 
microcolumns, and the peptides sequenced by tandem mass spectrometry. The information thus obtained 
can then be used to search sequence databases. 
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In the present study, chicken hepatoma DU249 cells undergoing apoptosis after 
treatment with aphidicolin have been examined. These studies have focused on 
establishing a reproducible method for the separation and detection of active caspases in 
cytosolic extracts. Thus, the information obtained by mass spectrometric sequencing of 
individual spots can later be related to a digital map of the caspase proteome. 
4.2 Results and discussion 
4.2.1 Labelling of active caspases in DU249 extracts 
In order to identify active caspases, cytosol from DU249 cells induced by 
aphidicolin and sequential treatment with nocodazole was labelled with Z-EK(bio)D-
aomk, an affinity labelling reagent 1232, 234] designed to mimic the EVD motif 
preferred by caspases. Control experiments have revealed that Z-EK(bio)D-aomk 
covalently modifies the large subunit of all active caspases [261]. Titration experiments 
performed by S. Sinha (Athena Neurosciences Inc., San Francisco, CA) revealed that as 
little as 1 ng of purified caspase-1 could be detected with this reagent. Due to the 
utilisation of biotin in the probe, a number of endogenous biotinylated proteins were also 
detected. To enable a distinction to be made between active caspases and endogenous 
biotinylated proteins, a control experiment was carried out. The apoptotic extract was 
first incubated with the affinity labelling reagent DEVD-aomk followed by Z-EK(bio)D-
aomk. Thus only the endogenous biotinylated proteins in the cytosol were detected. 
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4.2.2 Isolation of individual active caspases by 213-PAGE 
The objective, which was to establish a reproducible method for the detection of 
active caspases in chicken DU249 S/M extracts, proved to be a major challenge. The 
two-dimensional gels have to be run under absolutely identical conditions, since the 
spots on the silver stained gel corresponding to caspases which are due to be excised for 
mass spectrometric analysis, are identified by overlaying with the film from the 
duplicate Western blot. 
Apoptotic DU249 S/M extract, in which active caspases were labelled with the 
affinity label Z-EK(biotin)D-aomk, was loaded onto a pH 4.0-7.0 Immobiline Drystrip 
(Pharmacia) and subjected to isoelectric focussing. Similarly, apoptotic DU249 extract 
labelled with DEVD-aomk followed by Z-EK(biotin)D-aomk was loaded as a control for 
endogenous biotinylated proteins. After focussing the proteins according to their iso-
electric point, the Immobiline Drystrip was transferred to a SDS-PAGE (16%), on which 
the proteins are separated according to their monomeric molecular weights. 
Typically the experiments were carried out in triplicate. One of the gels was 
subjected to the silver staining protocol to reveal the proteome of the cytosolic extract 
(see Fig 4.2); using this method as little as I ng of protein in a particular spot can be 
visually detected. The other gels were subjected to the Western blotting procedure, in 
which the proteins are transferred from the gel onto nitro-cellulose. Thus the Western 
blot corresponding to the sample which was labelled with Z-EK(biotin)D-aomk revealed 
both endogenous biotinylated proteins and active caspases when treated with a 
streptavidin-horseradish peroxidase conjugate and revealed by enhanced chemo-
luminescence (ECL) (see Fig 43). The control experiment, which was labelled with 
DEVD-aomk followed by Z-EK(biotin)D-aomk, revealed only the endogenous 
biotinylated proteins when subjected to the same procedure (see Fig 4.4). Thus analysis 
of the Western blots of both DEVD-aomk and Z-EK(biotin)D-aomk labelled SIM 
extracts revealed the identity of both active caspase species and endogenous biotinylated 








IR 7_ ~-  4 1 47.5 32.5 




Figure 4.2 Silver-stained 2D PAGE of apoptotic DU249 cytosol 
Silver staining of high resolution two-dimensional poly-acrylamide gel-electrophoresis of apoptotic 
chicken DU249 cytosol reveals the proteome of the cell-line. The 15-35 kDa mass range contains the spots 
corresponding to caspase large subunits. 
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Figure 4.3 Western blot revealing active caspase species and endogenous biotlnylated proteins 
Analysis of Z-EK(biotin)-D-aomk labelled chicken DU249 SIM extracts by high resolution two-
dimensional gel electrophoresis and imtnunoblotting. Visualisation by immunostaining with the secondary 
antibody streptavidin-horseradish peroxidase and enhanced chemo-luminescence reveals the active 
caspase species and endogenous biotinylated proteins. 
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Figure 4.4 Western blot revealing endogenous biotinylated proteins 
Analysis of DEVD-aomk followed by Z-EK(biotin)D-aomk, labelled chicken DU249 S/M extracts by 
high resolution two-dimensional gel electrophoresis and immunoblotting. Visualisation by 
immunostaining with the secondary antibody streptavidin-horseradish peroxidase and enhanced chemi-














Lp* I [lUll 
Figure 4.5 Active caspase species and endogenous biotinylated proteins 
Comparison of the Z-EK(biotin)D-aomk and DEVD-aomk labelled chicken hepatoma cytosolic extracts 
identified the position of endogenous biotinylated proteins (blue circles) and thirty active caspase species 
(red circles). 
4.2.3 Discussion 
Analysis of affinity labelling experiments by two-dimensional SDS-PAGE 
revealed that chicken hepatoma DU249 cells undergoing aphidicolin-induced apoptosis 
contain roughly thirty distinct spots corresponding to active caspase species (see Fig 
4.5). 
At present only fourteen mammalian caspases have been identified thus 
suggesting the presence of multiple active forms of a number of caspases. These results 
consolidate earlier findings in human leukaemia HL-60 cells undergoing etoposide-
induced apoptosis [261]. The various forms of the enzymes could arise from alternative 
splicing of the transcripts [268], alternative processing of the proenzymes, and/or 
posttranslational modification of the processed subunits [71, 261]. 
The identification of each of these active caspase species and their post-
translational modifications should now be possible through the mass-spectrometric 
analysis of the individual spots. 
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4.3 Materials and methods 
4.3.1 Preparation apoptotic extract (See 33.1) 
4.3.2 Caspase labelling 
To 100 .tl apoptotic extract add 1 ILI Z-EK(bio)D-aomk (100 tiM stock) 
Label for 15 min at 37°C 
For control of endogenous biotinylated proteins: 
To 100 ILI of apoptotic extract add I tLI DEVD-aomk (100 tLM stock) 
Label for 15 min at 37°C 
Then add 1 l Z-EK(bio)D-aomk (100 tLM stock) 
Label for 15 min at 37°C 
4.3.3 Methanol/chloroform precipitation 
To 100 IAI of protein sample add 400 i1 of methanol (HPLC) and vortex 
Add 100 l of chloroform and vortex 
Add 300 pI of ddH2O and vortex 
Centrifuge at 13000 rpm (13,793 x g) for 2 mm (Heraeus Biofuge) 
Carefully draw off upper phase and discard (proteins lie on interface) 
Add to the protein containing fraction 300 tLI of methanol and vortex 
Centrifuge at 13000 rpm (13,793 x g) for 2 mm (R.T.) (Heraeus Biofuge) 
Discard the supernatant 
Dry pellet for 5 min at room temperature (Pellet can be stored for months @ -20°C) 
Resuspend in adequate buffer 
4.3.4 First-dimension, isoelectric focusing 
(Multiphor 11 electrophoresis unit with lmmobi1ine' dry-strip) 
Thaw 2.5 ml aliquot of rehydration stock solution and add 7 mg DTT 
Add 200 jsl of this solution to protein pellet and dissolve 
Pipet rehydration solution into slots of rehydration tray 
Place IPG strip with gel side down onto solution 
Overlay IPG strip with IPG covering oil 
Allow strips to rehydrate at room temperature overnight 
Switch on cooling-unit and allow to establish 18°C 
Pipette approximately 10 ml of IPG cover fluid onto cooling plate 
Position immobiline drystnp tray on the cooling plate 
Pipette approximately 15 ml of IPG cover fluid onto drystrip tray 
Remove IPG strips from reswelling tray and rinse briefly with water 
Position rehydrated strips into adjacent grooves of the drystrip tray (acidic side 
towards the anode) and align 
Place moistened electrode strips across the cathodic and anodic ends of the strips 
(allow partial contact with gel surface of strips) 
Position electrodes and press down 
Apply IPG cover fluid to completely cover the IPG strips (approximately 80 ml) 
Place cover and run isoelectric focussing protocol overnight 
4.3.5 Second-dimension, SDS-PAGE 
(Hoefer SE 600 system) 
Thaw 10 ml SDS equilibration buffer and add 200 mg DTT 
Place IPG strips into individual tubes of SDS equilibration buffer 
Cap the tube, place on a rocker and equilibrate for 15 mm 
Drain excess equilibration buffer with moistened filter paper 
Prepare the gel solution in a vacuum flask, omitting the TEMED and (NH 4)2Sg04 
Stopper flask and apply a vacuum for several minutes whilst swirling 
Add the TEMED and ammonium persulfate and gently swirl to mix 
Pour the PAGE gel and overlay with 0.5 ml t-butanol 
After a minimum of 1 hour for polymerisation, remove overlay and rinse with ddH 20 
Dip IPG strip in the SDS electrophoresis buffer to lubricate and position on gel 
Apply molecular weight markers in separate lane 
Seal IPG strip in agarose to prevent movement 
Assemble electrophoresis unit and add SDS electrophoresis buffer 
Run electrophoresis for ca. 16 hours at 12 mA per gel 
Upon completion remove gels from apparatus 
4.3.6 Silver-staining protocol for mass spectrometry 
Fix the gel in 50% methanol/ 5% acetic acid for 20 mm. 
100 nil methanol 
90 ml ddH.,0 
10 ml acetic acid 
Wash for 10 min in 50010 methanol (can be left ON here) 
100 ml methanol 
100 ml ddH,0 
Wash 3 X 10 min with ddH 20 
Put silver solution at 4°C 
Sensitise by 1 min incubation in 0.02% sodium thiosulfate 
200 ml ddH20 
800 1LI sodium thiosulfate 5% 
Rinse 2 X 5 min in ddH20 (2 X 4 min & drain) 
It is important not to rinse any longer! 
Submerge the gel in chilled 0.1% silver nitrate solution and incubate at 4°C for 20 
min. (this can be increased up to 1 h for better sensitivity) 
8 ml silver nitrate 23% 
192 ml H20 
Rinse 2X l  min in ddH2O* 
Develop 0.041% formaldehyde in 2% sodium carbonate 
108 itI of 37% formaldehyde 
2 g Na carbonate 
ddH20 to 100 ml 
Wash gel with 5010 acetic acid for 2 min 
Store gel in 1% acetic acid at 4°C until analysed. 
* For a batch of gels, leave all gels in silver and just take one gel at the time from step 7 
onwards 
4.3.7 Solutions 
Rehydration stock solution with !PG Buffer 
Final concentration Amount 
Urea 8M 12g 
CHAPS 2% (w/v) 0.5 g 
IPG Buffer 2%(vlv) .500 p1 
Bromophenol blue trace (a few grains) 
ddH20 to 25 ml 
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SDS equilibration buffer 
Final concentration Amount 
1.5MTris-CI,pH8.8 50 m 6.7m1 
Urea 6 M 72.07 g 
Glycerol (87%) 30010 (vlv) 69 ml 
SDS 2% (w/v) 4.0 g 
Bromophenol blue trace (a few grains) 
ddH20 to 200 ml 
4X Resolving gel buffer 
Final concentration Amount 
Tris base 1.5 M 1.81.5 g 
'h1'20 750 ml 
Conc. HC1 adjust to pH 8.8 
DdH 2O tol000ml 
SDS electrophoresis buffer 
Final concentration Amount 
Tnsbase 25mM 15.1g 
Glycine 192 mM 72.1 g 
SDS 0.1% (wlv) 5.0 g 
DdH20 To 5000 ml 
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Agarose sealing solution 
Final concentration Amount 
SDS electrophoresis buffer 100 ml 
Agarose 0.5% 0.5 g 
Bromophenol blue Trace A few grains 
Gel solution (16%) 
8 m 20m1 40m1 
4X resolving gel buffer 2 ml 5 ml 10 ml 
Acryl/Bis acrylamide 43 ml 10.5 ml 21.5 ml 
DdH20 1.7 ml 4.5 ml 8.5 ml 
APS(10%) 50jil 125 jl 250 Jul 
TEMED 5jsl 12.5 jsl 25s1 
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Chapter 5 Conclusions & Future prospects 
5.1 Conclusions 
Results presented in this thesis are research tools, which will provide novel methodology 
for the study of the role of caspases in apoptotic execution. First, a novel caspase 
inhibitor was synthesised, which will allow the specific detection of active caspase 
species in vitro. Second, a method was established for the affinity chromatography of 
caspases from apoptotic extracts. This purification method will provide the means to 
obtain sufficient amounts of a caspase fraction required for further studies. Finally, I 
instituted reproducible methodology for the separation and identification of active 
caspase species by two-dimensional gel electrophoresis. 
5.2 Techniques 
Our laboratory has developed several cell-free models that make the biochemical 
dissection of apoptotic execution possible, in particular focussing upon the assessment 
of the roles and activities of the caspases [269]. 
Affinity labelling reagents provide a powerful tools for the detection of active caspases. 
When combined with chemi-luminescent substrates, picogram levels of active proteases 
can be detected. 
High resolution two dimensional polyacrylamide gel electrophoresis (213 PAGE) is 
today considered the method with the highest resolution for the separation of complex 
protein mixtures such as those present in eukaryotic cells [265]. The 2D PAGE 
technology separates proteins both in terms of their isoelectric point (p1) and molecular 
weight. Usually one chooses a condition of interest and lets the cell reveal the global 
protein expression response, as all detected proteins can be analysed both qualitatively 
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and quantitatively (relative abundance, post-translational modifications, co-regulated 
proteins etc.) in relation to each other. 
Immunoblotting in combination with Enhanced Chemiluminescence (ECL) detection 
can reveal as few as 1000 molecules per cell. Low abundance proteins, like caspases, 
can be visualised either by increasing the sensitivity of the detection procedures, and/or 
by the analysis of subcellular fractions or partially purified protein samples. The novel 
peptidyl acyloxymethylketone affinity labelling reagent, employing dimtrophenyl 
functionality, which we have developed in the duration of my Ph.D. studies, will allow 
caspase detection on the nitro-cellulose immunoblot with extraordinary sensitivity, 
without staining of unlabeled proteins. 
Mass spectrometry is now the method of choice for protein identification and for the 
characterisation of post-translational modifications. The molecular weight of a protein is 
insufficiently discriminating; thus most approaches to protein identification rely on 
proteolysis with trypsin and analysis of the resulting peptides, often without any further 
separation. The increasing sensitivity of mass spectrometers combined with the rapid 
growth of protein and EST databases makes this a very powerful approach. 
For the analysis of the caspase proteome I propose to use both Matrix-assisted laser-
desorption-ionisation time-of-flight (MALDI-TOF) [270] and tandem mass 
spectrometric (MS/MS) quadrupole time-of-flight (Q-TOF) [271, 2721 technology for 
the analysis of individual caspase species isolated from 2D PAGE. Using mass-
spectrometrically derived peptide masses alone or mass and sequence together, current 
protein or expressed sequence tag (EST) databases can be rapidly searched. In addition, 
Q-TOF mass spectrometry can identify numerous post-translational modifications by 
comparison of the peptide sequence data generated, with hypothetical data of post-
translational modifications generated by a computer using protein sequences. 
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5.3 Proposed future directions 
Studies of cytosolic extracts and nuclei of HL-60 cells during etoposide-induced 
apoptosis on 2D PAGE, have revealed up to 30 different spots corresponding to 
activated caspases. Several of these were shown to be different forms of the same 
caspase [261]. Furthermore, a comparison of caspase activation and subcellular 
localisation in HL-60 and K562 cells undergoing etoposide-induced apoptosis using 2D 
PAGE showed surprising differences in the caspase species that were activated and also 
in the subcellular distributions of the active caspases [273]. 
Our working hypothesis is that many of these caspase species correspond to different 
post-translational modifications and/or proteolytic processing of the caspase repertoire. 
The purpose of the experiments described below is to characterise the active caspase 
proteome in one or two reference human cell lines, hopefully assigning every spot to a 
known caspase gene product. Provided that highly standardised two-dimensional gels 
are run, this information can be immediately used to characterise the pattern of caspase 
activation in various human cell lines and in response to different proapoptotic stimuli. 
Subsequent experiments will have the goal of identifying the posttranslational 
modifications and processing differences responsible for the characteristic mobility of 
individual two-dimensional gel spots. This information will then suggest possible 
experimental follow-ups, including mapping sites of phosphorylation, identification of 
the relevant kinases, and genetic and biochemical analysis of the consequences of 
phosphorylation or other modifications. 
As a source of active caspases, we intend to induce apoptosis in two established human 
cell lines, one from acute myelomonocytic leukaemia (HL-60), and the other from 
chronic myelogenous leukaemia (K562). In order to test the possibility of modifications 
varying with the apoptosis inducer, we will expose both cell lines to chemotherapeutic 
inducers such as the topoisomerase H poison etoposide, and the kinase inhibitor 
staurosponne. In control experiments using non-apoptotic cells we expect to be unable 
to detect any active caspase species. Highly concentrated (up to 40 mg/ml) apoptotic 
cytosolic extracts of tissue culture cell lines will be prepared by synchronisation of the 
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cells with aphidicolin followed by a nocodazole block, as in the cell free system already 
set up for DU249 cells [260, 274]. Active caspase species will be affinity labelled with 
the novel 2,4-dinitrophenyl (DNP) peptidyl acyloxymethylketone inhibitors. Caspase 
species will be separated from one another, using 213-PAGE. Individual spots, 
representing individual proteins, will be visualised by silver staining. Immunoblotting 
using anti-DNP antibodies will reveal the distribution of caspase species on a duplicate 
gel. Characterisation of individual caspase species will be carried out by excision of 
individual spots, chemical/enzymatic digestion, and high performance liquid 
chromatography (HPLC) followed by mass spectrometric analysis. Mapping, 
quantitation and subsequent comparative analysis will create a digital map of the caspase 
proteome. 
Through these experiments we will be able to: a) reliably identify individual active 
caspases in apoptotic extracts under the induction of variable apoptotic stimuli; b) 
resolve the number of active forms of each gene product to be activated; c) determine 
the variability of the caspase proteome between different cell types and methods of 
apoptotic induction, and d) identify some sites and/or types of post-translational 
modifications. Furthermore, the outcome of these experiments can be confirmed on a 
genetic level, for instance by mutagenesis of the phosphorylation sites to alanine 
residues, thereby abolishing phosphorylation. The spots corresponding to 
phosphorylated caspase species should disappear from the 2D gel. This methodology, 
using DNP inhibitors, 2D PAGE and MS, will be applicable to clinical materials where 
apoptotic activities may vary between diseased and control cells. 
Appendices 
Appendix 1 
Selected data for naturally occurring amino-acids 
Name Symbol Formula MW Res. Wt. 
Alanine Ala A C3H7NO2 89.095 71.079 
Arginine Arg R C6H 14N402 174.204 156.189 
Asparagine Asn N C4H8N,03 132.120 114.105 
Aspartic acid Asp D C4H7N04 133.105 115.089 
Cysteine Cys C C3HNO2S 120.151 102.135 
Glutamic acid Glu E C5"04 147.132 129.116 
Giutamine Gin Q C5H10N203 146.147 128.132 
Giycine Gly G C2H5NO2 75.068 57.052 
Histidine His H C6H9NO2 
 
155.138 137.142 
Isoleucine lie I C6H 13N0, 131.176 113.161 
Leucine Len L C6H13NO2 131.176 113.161 
Lysine Lys K C61 ­114N202 146.191 128.175 
Methionine Met M C5H11 NO2S 149.213 131.198 
Phenylalanine Phe F C9H11NO2 165.194 147.178 
Proiine Pro P C5H9NO2 115.133 97.118 
Serine Ser S C3H7NO3 105.094 87.079 
Threomne Thr T C4H9NO3 119.121 101.106 
Tryptophan Trp W C 11 H 12N202 204.230 186.215 
Tyrosine Tyr Y C91-1 1 1NO3 181.193 163.178 




Species occurring in multiple sequence alignment 
Caenorhabditis elegans Nematode worm 
Caenorhabditis vulgaris Nematode worm 
Canis familiaris Dog 
Cricetulus longicaudatus Long tailed hamster 
Danio rerio Zebrafish 
Drosophila melanogaster Fruitfly 
Equus cabailus Horse 
Felis catus Cat 
Gallus gallus Chicken 
Homo sapiens Human 
Hydra vulgaris Freshwater anemone 
Mesocricetus auratus Golden hamster 
Mus musculus House mouse 
Oncorhynchus mykiss Rainbow trout 
Ovisaries Sheep 
Rattus norvegicus Norwegian rat 
Spodoptera frugiperda Fall armyworm 
Xenopus laevis African clawed frog 
[Li:;1 
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Caspase substrates: Proteins cleaved by caspases during apoptosis (adapted from Earnshaw et al. [38]) 
Site Caspac : Prposcd ellect oF cica age Rcicicnce 
DQTD G 3 Gelsolin Calcium-insensitive actin cleavage [273. 276] 
SRVD 0 ? Gas-2 (growth arrest-specific gene product 2) Cytoskeleton rearrangement [277] 
DETD S 3 Fodnn site I Plasma membrane blebbing [278-282] 
DEVD S 3 B II spectrin Unknown [281] 
DSLD S 3 Fodnn site II Plasma membrane blebbing 
VEVD A 3,6,7 Cytokeratin 18 (note DALD S in Nicholson!!) Unknown [283,284] 
XXXD X 3 6 Catenin Unknown 
ELPD 0 3 Actin Reverses DNase I inhibition [285-2901 
XXXD X 7 Kinectin (kinesin receptor) Unknown [2911 
XXXD X 8 Plectin Abolishes cross-linking cytoplasmic filaments [2921 
XXXD X ? HEF1 (human enhancer of filamentation 1) docking at focal adhesion sites [293] 
Nuclear proteins 
VEID N 6 Lainin A Nuclear lamina disassembly [11,57. 294, 2951 
VEVD S 6,?3 Lamin B Nuclear lamina disassembly [9-11,158,295-2971 
DSLD L 3,6 NuMA (nuclear-mitotic apparatus protein) Nuclear shape changes [298-303] 
DXXD X 3 HnRNP-C 1/C2 (heteronuclear ribonucleoproteins C 1&C2) RNA processing  
XXXD X ? SAF-A/hnRNP-U (scaffold attachment factor A) Unknown  
(heteronuclear ribonucleoprotein U) 
XXXD X 3 hnRNP-A 1 (heteronuclear nbonucleoprotein Al) Unknown [124] 
DGPD G 3 U 1-70K snRNP (70 kDa component of U  small nuclear JRNA processing (299,306-308] 
riboprotein) 
DVPD C 3,6,7 mdm2 (murine double-minute chromosome oncogene) Unknown, still binds p53 [309,310] 




























LAP2 (lamin associated protein 2) 
Nup153 (153 kDa nucleoporin) 
Pr icin nvk ed in I)NA mctabhm anti it pair 
PARP (poly(ADP-ribose)polymerase) 
DNA-PKcs (catalytic subunit of DNA dependent protein kinase) 
DNA-RFC 140 (140 kDa subunit of DNA replication factor C) 
Topoisomerase 1 
RadS 1 (mammalian RecA recombinational repair homologue) 
MCM3 (minichromosome maintenance protein 3, nuclear 
replication factor) 
Proc'r ktnascs 
PKCb (protein kinase C) 
PKCt 
PKCt 
PRK2 (Protein kinase C-related kinase 2) 
PKN (protein kinase N) 
CaMK-IV (CalCalmodulin dependent protein kinase IV) 
PAK-2 (p21-activated protein kinase-2 
PITSLRE kinase (p34 CDC2-related protein kinases) site! 
PITSLRE kinase site II 
P!TSLRE kinase site III 
Mst 1 kinase (mammalian homologue of yeast Ste20 kinase) 
Mst2 kinase 
FAK (Focal adhesion kinase) site I 
FAK(Focal adhesion kinase) site U 
MEKK-1 (MEK kinase-1) 
Wee 1 (Wee] kinase, inhibitor of cdc2 and cdk2) 
p59 FYN (src-like tyrosine kinase p59 FYN) 
Aktl (protein kinase B) 
Signal transduction and gene e' prc.sion proteins 
Pro-interleukin 10 site I 
Unknown 	 [312] 
Unknown 1[3121 
I,Synthesis of poly(ADP-ribose) [9, 12,25.84, 299, 
308,313-3161 
.Activity [308,317-321] 
N-terminal fragment inhibits DNA replication [322,323] 
Unknown [9,299,324,325] 
Inactivates recombinase function [326,327] 
Inactivates Mcm-complex, abrogates DNA [328] 
tutively active kinase 	 [329,330] 
Constitutively active kinase 332] 
Constitutively active kinase 333] 
? Constitutively active kinase  
Constitutively active kinase  
Unknown  
Constitutively active kinase [337, 338] 
Constitutively active kinase [339,340) 
Constitutively active kinase 
Constitutively active kinase 
Constitutively active kinase [341, 342] 
Constitutively active kinase [342] 
Loss of paxillin binding, ? trans-location nucleus & [343-345] 
1.activity 
J, Binding to 14-3-3, A subcellular distribution [346-348] 
Probably inactivation, leading to Cdk activation  
Unknown  
Unknown  

























XXD X 3 
NIDN 3 
SVDL 13,7 
Pro-interleukin IP site II 
prolL-16 (Pro-interleukin 16) 
prolL-18 (Pro-interleukin 18) 
rabaptin-5 (Rab5 GTPase effector protein) 
RasGAP (Ras GTPase-activating protein) 
ho GDP-dissociation inhibitor, 1)4) 
ein phosphatase 2A) 
so1ic phospholipase A 2) 
al transducer and activator of transcription factor) 
clear factor-KB transcription factor) 
or of Rel/NFKB) 
erol regulatory element-binding proteins) site I 
erol regulatory element-binding proteins) site II 
Calpastatin site I (Calparn inhibitor) 
Calpastatin site II 
Calpastatin site III 
Spi (transcription factor Spi) 
SRP p72  (72 kDa protein of signal recognition particle) 
Cbl (Cbl protooncogene product) 
negative regulator of receptor tyrosine kinase signaling 
AMPA receptors 
Cell cycle regulator\ uiJ prolit cr.thon proteins 
p21 waf 1 (21 kDa inhibitor of cyclin dependent kinases) 
p27 kipl (27 kDa cyclin dependent kinase inhibitor) 
Rb (retinoblastoma gene product) 
CDC27 (CDC27 component of anaphase-promoting complex) 
APC (adenomatous polylxsis coli oncosuppressor protein) 
n\t\ ed III huintn gcnci.: Ulcisc 
Huntingtin (Huntington's disease gene product) 
Key mediator of inflammation 
T lymphocyte chemotaxis [353] 
Induces synthesis of interferon ' [138-140,354] 
Loss of endosome fusion ability [355] 
Inactivation of survival signaling extracellular [351.3561 
receptors 
No demonstrated effect  
Activity toward non-cdk substrates  
Activation [359-3611 
J,Transcription after interferon a or  [3621 
j,NFKB-dependent transcription  
?Generates constitutive inhibitor of NFKB  
Non-physiological cleavage  
Non-physiological cleavage 
Product facilitates ligand withdrawal-induced  
apoptosis 
Decreased inhibition of calpain [3671 
Decreased inhibition of calpain 




Unknown 	 I [371] 
Loss of N-terminal cdk inhibitory domain from [372,3731 
nucleus 
4p27 in cyclin E-cdk complexes [372] 
Unopposed E217- 1 action [374,375] 
J,Ubiquitin ligase, stabilization of cyclins A & B [349] 
Abolishes 	-catenin binding [376,377] 




























WVRD S 3.4.6.7 
Atrophin-1 (Dentatorubral pallidalysian atrophy gene product) 
Presenilin- 1 
Presenilin-2 
ATM (ataxia telangieectasia mutated gene product) 
Ataxin-3 (gene product defective in spinocerebellar ataxia type 3) 
SBMA-AR (androgen receptor defective in spinal bulbar muscular 
atrophy) (Kennedy's disease) 
n-APP (amyloid-beta precursor protein) 
\ptouu rcu1ut&F\ prtcins 
Bcl-2 (B-cell lymphoma gene 2 product) 
Bcl-X (long version of Bcl-2-related gene product X) 
FUPL 
Bid (BH3 interacting domain death agonist) 
Bax 
ICAD site I (Inhibitor of caspase-activated deoxyribonuclease) 
ICAD site 11 
function untn 	ri 
Hsp9O (90 kDa heat shock protein) 
UbqCE NEDD4 (ubiquitin conjugating enzyme, 
neural-expressed developmentally downregulated gene 4 protein) 
p28 Bap3 1 (BCR-associated protein, 28 kDa Bcl-2-interacting 
protein) 






No known effect 
Unknown 





Generates pro-apoptotic fragment 
Generates pro-apoptotic fragment 
Unknown 
Generates pro-apoptotic fragment 
Unknown 
Uberates active CAD 




C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 


















WVRD S 3,6,7 Procaspase 5 
EADS 
(XXD X 
)VVDN 3,6 Procaspase6 
EVDA 
['ETDA 
QADS 3,7,8,9 Procaspase7 
)SVDA 
IETD S 8 Procaspase 8 
EMD L 
.EQD S & TMSD C (alternative splicing sites) 
'EPD A 9 Procaspase 9 
)QLD A 
(XXD X 
EADS 10 ProcaspaselO 
QTD V 
(XXD X 3,6,7 Procaspase 13 
((XD X 
(XXD X 
(XXD X 3,6,7, Procaspase 14 
(XXDX ?14 
(XXD X 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
prodomain 
C-terminus large subunit 
linker between large & small subunit 
prodomain 
C-terminus large subunit 
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